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1 Summary 
Microglia comprise the resident tissue macrophage population in the brain 
parenchyma. They acquire a variety of functions in health and disease and are thus 
one of the most studied cell types regarding their contribution to neurological disease. 
In Alzheimer’s disease, deposition of amyloid-β occurs in senile plaques and leads to 
alterations of the microglial phenotype. This feature is mimicked in transgenic mouse 
models developing cerebral β-amyloidosis. How microglia influence onset and 
progression of Alzheimer’s disease remains incompletely understood despite many 
studies.  
Microglia are developmentally distinct from tissue macrophages in other organs and 
invade the brain early in embryogenesis. A long lifetime has been attributed to 
microglia; however, this has only scarcely been studied. Today, technological 
advances in the development of transgenic mouse models and in vivo microscopy 
allow for the in depth analysis of microglial turnover. In the first study presented here, 
we used genetic tools to label individual microglia and followed them in vivo by two-
photon imaging. Long-term imaging over many months revealed that microglia are a 
long-lived cell population with low turnover rates. Furthermore, the rates of 
microglial proliferation and death were equal, matching previous reports that 
microglial cell numbers stay stable over time. In line with previous studies, higher 
proliferation rates were found in a mouse model of cerebral β-amyloidosis. 
Nevertheless, both in health and disease conditions, microglia lived many months and 
a proportion of microglia persisted throughout the entire lifespan of mice. 
The long lifetime of microglia renders them suitable for the characterization of innate 
immune memory, a recently emerged concept, in the brain. While it was previously 
believed that only adaptive immune cells depict memory characteristics, recent 
reports have demonstrated immune memory also in cells of the innate immune 
system. Herein, a priming immune stimulus leads to a long-lasting change in the 
activation state of the innate immune cell, thereby modifying its response towards a 
secondary stimulus. In particular, two paradigms can be distinguished: a heightened 
response has been termed training, while a reduced response is called tolerance.  
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Our second study aimed to reveal whether training and tolerance are inducible in the 
brain and could be long-lasting modifiers of later occurring neurological disease 
pathology. We demonstrate that following peripheral immune stimulation with 
lipopolysaccharides or certain cytokines acute training and tolerance effects were 
evident in the brain. Furthermore, training and tolerance had opposing effects on 
much later occurring neuropathology of stroke and early stages of cerebral β-
amyloidosis. Microglial enhancer landscape, gene expression, and function differed in 
response to peripheral immune stimulation with lipopolysaccharides, indicating long-
term microglial reprogramming. Therefore, our study provides evidence for long-
lasting innate immune memory in microglia that is epigenetically encoded and is 
sufficient to alter later developing neuropathology.  
In the third study, we investigated whether training and tolerance modify amyloid 
plaque structure and neurotoxicity in mice with more advanced cerebral β-
amyloidosis. Strikingly, modifications of amyloid plaque structure were evident 
9 months after induction of training and tolerance, and occurred concomitantly with 
alterations in microglial function. In particular, peripheral training and tolerance 
stimuli altered the phenotype of plaque-associated microglia or reduced their number, 
respectively. Both impaired microglial barrier function, a recently described feature of 
microglia around amyloid plaques in Alzheimer’s disease mouse models and patients. 
Importantly, modulation of microglial function, as induced by peripheral immune 
stimulation, altered amyloid plaque structure and thereby increased plaque-associated 
neurotoxicity. These results indicate that changes in microglial function contribute to 
neuronal damage by modulating amyloid structure and that such changes may occur 
in response to peripheral inflammatory events. 
In summary, this thesis demonstrates that microglia are exceptionally long-lived cells 
with the capability to form persisting immune memory. Peripheral immune 
stimulation epigenetically reprograms microglia to acquire distinct phenotypes that 
subsequently modify pathological features of cerebral β-amyloidosis. Therefore, we 
identified epigenetic microglial memory of peripheral inflammation as an essential 
modifier of neurological diseases.  
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2 Synopsis 
2.1 Innate immune memory 
Every organism lives in constant interaction with microorganisms – some form 
symbiotic relationships with the host, while others are pathogenic and cause serious 
disease. The immune system evolved as a defense mechanism against harmful 
pathogens and relies on a complex interplay between immune cells and humoral 
factors. Two main branches of immunity, termed innate and adaptive immunity, exist 
in mammals (Parkin & Cohen, 2001).    
The innate immune system is present in all metazoans and provides the first line of 
defense against infection and tissue damage. The innate immune system relies on 
sensing structures common to broad classes of microorganisms, so called pathogen-
associated molecular patterns (PAMPs). These are recognized by pattern recognition 
receptors (PRRs) on innate immune cells including macrophages, granulocytes, and 
natural killer cells (Akira et al., 2006). As a result, soluble mediators such as 
cytokines, chemokines, and complement proteins, are locally produced, initiate 
phagocytosis, recruit other immune cells, and exert multiple effects on the body.  
In higher organisms such as mammals, adaptive immunity evolved as a second arm of 
the immune system to provide an additional layer of defense. While the main task of 
innate immunity is to produce a fast protective response and limit damage to the host, 
adaptive immunity provides a slower but more specific immune response that will 
protect the host against reinfection with the same pathogen (Dempsey et al., 2003). 
Innate immunity plays a key role in initiating the adaptive immune response through 
the action of antigen-presenting cells that in turn activate adaptive immune cells, the 
lymphocytes (Iwasaki & Medzhitov, 2015). The adaptive immune response is 
mediated by clonal expansion and differentiation of antigen-specific B- and T- 
lymphocytes into effector and memory cells. Antibody-producing B-lymphocytes, 
cytotoxic T-lymphocytes, and activated innate immune cells then cooperate to clear 
pathogens. After resolution of infection, memory lymphocytes reside in the body and 
initiate a faster and enhanced immune response upon reinfection with the same 
pathogen (Dempsey et al., 2003).  
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Despite playing different roles during the course of an immune reaction, innate and 
adaptive immunity cooperate intimately and cannot be viewed as distinct entities. 
Several immune cells contribute to both arms of immunity and are not readily 
classifiable into one of the two systems. Furthermore, the distinctions between innate 
and adaptive immunity have started to fade regarding memory formation (Hamon & 
Quintin, 2016).  
Immunological memory refers to the immune system’s ability to respond with an 
adapted immune response, which differs from the naïve response, to a secondary 
infection. For innate immune cells, memory characteristics have only recently been 
described and attributed to lasting epigenetic and transcriptional changes after 
stimulus cessation (Netea et al., 2016; Ostuni et al., 2013). These changes occur as a 
result of the first immunological insult (termed priming stimulus) and lead to 
persistent alterations in the cell’s functional state, thereby mediating a differential 
response towards a secondary immune stimulus (Figure 1). This differential response 
can be heightened (termed trained immunity or training) or suppressed (termed 
tolerance) compared to the naïve immune response (Quintin et al., 2014).  
 
 
 
 
 
 
 
 
 
  
Figure 1: Innate immune memory. Following a priming stimulus, the cellular activity state 
is altered long-term. Upon a secondary immune stimulus, cells respond with an adapted 
immune response, which can be heightened (training) or suppressed (tolerance). Adapted 
from Quintin et al., 2014. 
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While immune memory in adaptive immune cells is very specific to the encountered 
antigen, innate immune memory is in most cases non-specific (Hamon & Quintin, 
2016; Song & Colonna, 2018). Since innate immune memory is mediated by long-
lasting alterations of the cellular homeostatic state, the reaction to a broader range of 
subsequent stimuli is altered and thereby confers cross-protection to some up to now 
unresolved extent (Moret & Siva-Jothy, 2003; Netea et al., 2011; Pham et al., 2007).  
So far, innate immune memory has been described for NK cells, monocytes, and 
macrophages in response to a range of pathogens, including bacteria, fungi, viruses, 
and parasites (Hamon & Quintin, 2016; Netea et al., 2016). The most well known 
example of innate immune memory is endotoxin tolerance, which describes a 
refractory immune state induced by repeated or high-dose administration of 
lipopolysaccharide (LPS), a membrane component of Gram-negative bacteria. 
Endotoxin tolerance occurred in septic patients after the initial acute systemic 
hyperinflammatory response and persisted for at least 2 weeks (Monneret et al., 
2004). Epigenetic and transcriptional reprogramming underlie the refractory state of 
endotoxin-tolerant innate immune cells (Biswas & Lopez-Collazo, 2009; Foster et al., 
2007; Schaafsma et al., 2015; Shalova et al., 2015). However, the effects of LPS on 
the immune system are extremely diverse and depend largely on its dose and 
administration frequency. For example, low doses of LPS can have opposing effects 
and prime macrophages, subsequently inducing trained immunity (Deng et al., 2013; 
Zhang & Morrison, 1993). 
Other observations, such as the cross-protection of Bacillus Calmette-Guérin (BCG) 
vaccination against other non-mycobacterial diseases, have been known for a long 
time and only recently been studied in more detail (Netea & van Crevel, 2014; Arts et 
al., 2018). The beneficial non-specific effects of the BCG vaccine were now 
attributed to heightened cytokine production and altered functional states of 
peripheral monocytes (Arts et al., 2018; Kleinnijenhuis et al., 2012). Interestingly, the 
BCG vaccine and other inflammatory stimuli exert effects also on hematopoietic 
progenitor cells, resulting in their myeloid-biased proliferation (Christ et al., 2018; 
Kaufmann et al., 2018; Mitroulis et al., 2018). Thus, recent studies indicate that not 
only differentiated cells, but also certain progenitor and stem cell types, possess 
capacity for immune memory formation (Christ et al., 2018; Kaufmann et al., 2018; 
Mitroulis et al., 2018; Naik et al., 2017). 
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One of the best examples for trained immunity occurs following priming with β-
glucan, a component of the fungal cell wall. Stimulation of monocytes with β-glucan 
led to stable epigenetic histone modifications and transcriptional reprogramming, 
resulting in a metabolic shift towards glycolysis (Cheng et al., 2014; Quintin et al., 
2012; Saeed et al., 2014). Interestingly, β-glucan treatment partially reversed 
epigenetic and transcriptional alterations occurring after LPS-induced tolerance in 
vitro, indicating that training and tolerance confer modifiable epigenetic alterations on 
to some extent overlapping signaling pathways (Novakovic et al., 2016). The role of 
epigenetic and metabolic reprogramming in innate immune memory will be further 
discussed in chapter 2.5.2.  
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2.2 Microglia at a glance 
Microglia are the resident parenchymal macrophages of the central nervous system 
(CNS). They have been described and named by del Rio-Hortega in 1919 (Rio-
Hortega, 1919; Sierra et al., 2016) and comprise 5-12% of glial cells in the brain 
(Lawson et al., 1990).  Due to their wide array of functions they play a role in CNS 
development, circuit and synapse rewiring (Graeber, 2010; Parkhurst et al., 2013; 
Schafer et al., 2012), innate immune response, and have been implicated in 
neurological disease states (Gomez-Nicola & Perry, 2015).  
Under homeostatic conditions, microglia exhibit a ramified morphology and are 
constantly surveying the tissue environment by movement of their numerous 
processes (Davalos et al., 2005; Nimmerjahn et al., 2005). As innate immune cells, 
they participate in host defense and are equipped to respond to any alteration of the 
tissue environment. Microglia express a variety of PRRs to detect pathogen entry or 
injury to the brain (Kettenmann et al., 2011). Activation of PRRs can result in the 
release of inflammatory cytokines, chemokines, and induction of phagocytosis 
(Hanisch, 2002; Ransohoff & Cardona, 2010; Ransohoff & Perry, 2009). Under 
certain conditions, other cells – such as astrocytes, neurons, and invading peripheral 
immune cells – contribute to inflammatory processes in the brain (Heneka & 
O’Banion, 2007). However, inflammation in the brain has to be tightly controlled, as 
many pro-inflammatory cytokines are potent inducers of neuronal dysfunction and 
cell death (Ransohoff & Cardona, 2010). 
Changes from the surveying microglial morphology and function to different 
phenotypes were originally termed “microglial activation”. Up until recently, 
scientists categorized microglial and macrophage phenotypes into opposing activation 
states (previously termed M1 and M2), but it has become evident that this simplistic 
view cannot capture the full picture of their phenotypic diversity (Xue et al., 2014). 
Since the alterations that can occur in the brain environment are extremely pleiotropic 
and versatile, such are the microglial adaptive responses (Hanisch & Kettenmann, 
2007; Ransohoff & Perry, 2009). Therefore, an accurate description of microglial 
phenotypes in health and disease states can solely be achieved by in depth ‘omics’, 
e.g. transcriptomic or epigenomic, approaches. Recently, genome-wide approaches 
have been used to study macrophage and microglial phenotypes and led to the 
characterization of the microglial transcriptome and epigenome under different 
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conditions (Gosselin et al., 2014; Lavin et al., 2014; Orre et al., 2014). Analysis of 
the microglial transcriptome on a single-cell level has proven the substantial 
heterogeneity of microglial phenotypes and resulted in the description of molecular 
microglial profiles under different conditions (Keren-Shaul et al., 2017; Korin et al., 
2017; Mathys et al., 2017). This will be further discussed in chapter 2.5.2. 
Microglia originate from primitive hematopoiesis in the yolk sac of the early embryo 
and invade the brain during early embryonic development (Ginhoux et al., 2010; 
Hoeffel et al., 2015). Hence, microglial identity is established by a combination of 
developmentally determined and environment-dependent transcriptional networks 
(Gosselin et al., 2014; Mass et al., 2016; Matcovitch-Natan et al., 2016). Microglia 
reside in the brain throughout their life and are maintained by local self-renewal with 
no appreciable contribution from the peripheral hematopoietic system under 
homeostatic conditions (Ajami et al., 2007; Hashimoto et al., 2013). However, until 
recently, mechanisms of microglial network maintenance and turnover of microglia in 
vivo have only been scarcely studied and remained poorly understood. This topic will 
be discussed in depth in chapter 2.5.1.  
Understanding the turnover and lifetime of microglia in vivo is of particular 
importance for the study of long-term changes in these cell types, which might 
influence aging and neurodegenerative diseases. A concept reminiscent of trained 
immunity termed priming has been described to occur in microglia under certain 
circumstances (Haley et al., 2017). Priming has first been demonstrated in 
macrophages in vitro, wherein a primary stimulation heightened the cellular response 
towards a secondary stimulus (Henricson et al., 1993; Hirohashi & Morrison, 1996; 
Zhang & Morrison, 1993). Microglial priming is believed to be elicited by diverse 
stimuli such as aging, neurodegenerative disease, and acute or chronic systemic 
inflammation (Cunningham, 2013; Perry & Teeling, 2013). Applying priming stimuli 
such as systemic inflammation during particularly susceptible periods, i.e. pre- or 
neonatally, led to life-long alterations of the microglial phenotype that predisposed 
the brain to the development of neurodegenerative-like conditions (Krstic et al., 
2012). Evidence for immune memory in microglia, its mechanisms, and its 
consequences for neurological disease will be further discussed in chapter 2.5.2.  
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2.3 Characteristics of Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and 
has become increasingly epidemic with rising life expectancies (Dartigues, 2009; 
Holtzman et al., 2011). AD is a complex neurological disorder, in which a multitude 
of cellular processes go awry. However, on a molecular level AD is characterized by 
the presence of two aggregated hallmark proteins: amyloid-beta (Aβ) and tau, as first 
described by Alois Alzheimer in 1907. In every AD patient, Aβ is deposited in the 
brain parenchyma in the form of aggregated, insoluble, fibrillar structures called 
senile plaques (Glenner & Wong, 1984; Masters et al., 1985). The second disease 
hallmark is the presence of neurofibrillary tangles (NFT’s), intraneuronal inclusions 
mainly consisting of the hyperphosphorylated, aggregated microtubule-associated 
protein tau (Grundke-Iqbal et al., 1986; Kosik et al., 1986).  
Tragically, the molecular aggregation processes underlying disease development 
already start decades before onset of symptoms in patients (Jack et al., 2010). The Aβ 
peptide has been of immense interest to the scientific community because its 
misfolding and aggregation in amyloid structures is believed to mark the beginning of 
the disease process. In fact, the deposition of Aβ and resulting neuronal damage 
precedes symptom onset by about 15 years (Bateman et al., 2012). Once Aβ deposits 
form in the brain parenchyma due to a misbalance in its production and clearance rate, 
a series of reactions takes place that ultimately leads to symptoms of AD. Multimeric 
Aβ aggregates activate the immune system in the brain (see chapter 2.4 for details), 
leading to an inflammatory reaction, the induction of neurofibrillary tangles, and 
ultimately synaptic and neuronal loss resulting in dementia. This series of events 
initiated by the aggregation of the Aβ peptide has been described as the amyloid 
cascade hypothesis (Hardy & Selkoe, 2002; Selkoe & Hardy, 2016). 
The Aβ peptide is generated by proteolytic cleavage of the transmembrane protein 
amyloid-precursor protein (APP) (Haass & Selkoe, 1993), a process occurring 
continuously throughout an individual’s life span (Haass et al., 1992). APP is cleaved 
first by β-secretase, resulting in the generation of a C-terminal fragment (CTF-β) 
(Vassar et al., 1999), which is subsequently processed by the γ-secretase complex. 
The γ-secretase complex cleaves CTF-β progressively between residues 37 and 43, 
leading to the liberation of Aβ isoforms with variable lengths into the extracellular 
space (Haass et al., 2012; Vassar et al., 1999). The most common isoform of Aβ in 
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healthy individuals is Aβ1-40, while AD patients often exhibit increased amounts of 
the more aggregation prone isoform Aβ1-42 (Hellström-Lindahl et al., 2009). The 
mechanism by which natively unfolded monomeric Aβ peptides are converted into 
aggregated structures with the distinct structural and histochemical properties of 
amyloids (e.g. cross β-structure, Congo red binding and concomitant birefringence) is 
still under debate. For aggregation prone amyloidogenic proteins such as Aβ, in vitro 
and in vivo evidence suggests a self-propagating nucleation-dependent polymerization 
process (Jucker & Walker, 2013), comparable to the templated protein misfolding 
occurring in prion disease. In a first step, Aβ misfolds into a β-sheet rich structure that 
subsequently forms a multimeric nucleus (also termed seed), which converts and 
incorporates other Aβ molecules into growing aggregates (Harper & Lansbury, 1997; 
Jarrett & Lansbury, 1993). The formation of the initial misfolded Aβ seed is a rare 
event that happens due to its unfavorable kinetics stochastically over a long period of 
time. The exact nature of the Aβ seed is still unknown and remains to be resolved 
(Jucker & Walker, 2013). However, once sufficient Aβ seeds have formed, growth of 
aggregates proceeds quickly and deposition of amyloid plaques starts, ultimately 
leading to neuron loss and symptoms of AD.  
AD can be subdivided into an early-onset familial and a late-onset sporadic form. 
Familial AD accounts for less than one percent of disease cases and is caused by rare 
dominantly inherited mutations affecting Aβ homeostasis (Bekris et al., 2010; 
Scheuner et al., 1996). All known familial mutations causing early-onset AD occur in 
proteins involved in Aβ generation (Crook et al., 1997; Goate et al., 1991; Mullan et 
al., 1992), namely APP and presenilin 1 and 2, the latter two being part of the γ-
secretase complex (Wolfe et al., 1999).  
Knowledge about the genetic causes for AD has been used to generate animal models 
to mimic the disease process. Many of the widely studied transgenic mouse models 
overexpress mutated human APP, sometimes in combination with presinilin 
mutations. In contrast to wildtype animals, these mice show age-dependent deposition 
of Aβ in parenchymal plaques and/or cerebral blood vessels (cerebral β-amyloidosis), 
accompanied by glial and neuronal alterations (Ashe & Zahs, 2010; Jucker, 2010). 
However, global neuron loss and NFT’s are lacking in mouse models with cerebral β-
amyloidosis (Bornemann & Staufenbiel, 2000; Howlett & Richardson, 2009), 
although early stages of tau pathology (i.e. hyperphosphorylation of tau) are evident 
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around amyloid plaques in some models (Kurt et al., 2003; Sturchler-Pierrat et al., 
1997). Despite these animal models not recapitulating all features of the disease 
process, they comprise useful tools for the study of the molecular aggregation process 
of Aβ and concomitant cellular changes in the brain. 
The vast majority of AD cases occurs sporadically, i.e. in the absence of a known 
disease-causing mutation, with symptom onset much later in life compared to familial 
AD patients (Bekris et al., 2010). However, the molecular cascade leading to disease 
pathogenesis is believed to be similar in sporadic and familial forms of AD. The risk 
of developing sporadic AD is determined by a combination of genetic (see chapter 2.4 
for details) and environmental risk factors (Reitz et al., 2011; Tosto & Reitz, 2013). 
Importantly, by far the biggest risk factor for the development of sporadic AD is 
aging (Reitz et al., 2011). Since Aβ is continuously produced throughout life, the 
chance for the stochastic formation of sufficient amounts of disease-initiating Aβ 
seeds increases with time. Moreover, cell regeneration is limited within the brain, 
resulting in gene expression changes with aging particularly in glial cells, which have 
Aβ clearance capability (Soreq et al., 2017). Low-grade chronic inflammation in the 
brain occurs with age as a result of alterations in cellular phenotypes; microglia are 
skewed towards adopting a more pro-inflammatory phenotype (microglial priming, 
see chapter 2.2) and simultaneously lose features implicated in ensuring brain 
homeostasis (Hefendehl et al., 2014; Lynch et al., 2010; Yu et al., 2002). Thereby, 
alterations of cellular functions with aging may predispose to the development of 
neurodegenerative processes and act in concert with the life-long continuous 
production of Aβ in the initiation of AD. 
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2.4 Inflammation in Alzheimer’s disease 
Historically, due to the view of the brain as an immunologically privileged organ, 
inflammation was not believed to contribute to AD and other neurological diseases. 
This concept has dramatically changed in the last two decades and led to a new field 
of research concentrating on the interaction between the immune and the nervous 
system in health and disease. Today, we know that a variety of immune cell subtypes 
exist in the brain (Korin et al., 2017) and drive inflammation in many neurological 
diseases (Heneka et al., 2014). Especially in AD, inflammation occurs and contributes 
to disease progression and neuronal loss (Heneka & O’Banion, 2007). 
The first hints about the contribution of immunology to neurological disease appeared 
upon discovery of inflammatory molecules such as complement, cytokines, and acute 
phase proteins, in AD brains (Akiyama et al., 2000). Since then, it has become 
evident that multimeric Aβ itself activates the immune system in several ways (Bate 
et al., 2004; Paresce et al., 1996; Rogers et al., 1992; Wang et al., 2004; Yan et al., 
1998). Microglia and astrocytes proliferate and accumulate around Aβ plaques 
(gliosis), a process accompanied by alterations in cellular function (Akiyama et al., 
2000; Itagaki et al., 1989). Furthermore, Aβ deposition in the brain alters the 
production of pro- and anti-inflammatory cytokines (Butovsky et al., 2005; Floden & 
Combs, 2006; Lee et al., 2002; Lindberg et al., 2005; Lue et al., 2001; Szczepanik et 
al., 2001). This altered inflammatory environment may propagate further amyloid 
deposition, the formation of NFT’s, and neuronal damage (Guo et al., 2002; Kitazawa 
et al., 2005; Kitazawa et al., 2011; Li et al., 2003; Sheng et al., 2000). Damaged 
neurons release danger-associated molecular patterns (DAMPs), which in turn 
activate PRR on microglia, thereby creating a feed-forward loop between 
inflammation and neurotoxicity (Block et al., 2007).  
Although Aβ is regarded as the disease-initiating cause of AD pathology, Aβ burden 
itself does not correlate with cognitive decline in patients (Edison et al., 2008; Lue et 
al., 1996). In contrast, increased inflammatory markers are significantly correlated 
with the occurrence and severity of dementia (Edison et al., 2008; Lue et al., 1996), 
implicating inflammation as a main contributor to memory impairment in AD. 
Interestingly, many risk factors for the development of AD are related to 
inflammation (Heneka et al., 2015). Local inflammatory insults to the brain, such as 
traumatic brain injury, as well as systemic infections and peripheral diseases with an 
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immune component, such as diabetes mellitus, increase the risk for AD (Heneka et 
al., 2014; Sims-Robinson et al., 2010). Acute peripheral infections in AD patients 
dramatically worsen disease symptoms and lead to irreversible long-term cognitive 
decline (Cunningham, 2013; Dunn et al.; Holmes et al., 2009). On the other hand, the 
long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) lowers the risk of 
developing dementia (Hoozemans et al., 2011), although therapeutic use of NSAIDs 
did not show beneficial effects in clinical trials. Nevertheless, these clinical 
observations and epidemiological studies connect local and systemic inflammation to 
the development and progression of AD. 
The impact of inflammation on neurological disorders has been further highlighted by 
genome-wide association studies (GWAS) that have linked variants in several 
immune-related genes to neurological disease (Gagliano et al., 2016; Guerreiro et al., 
2013; Hollingworth et al., 2011; Huang et al., 2017; Lambert et al., 2013; Naj et al., 
2011; Sims et al., 2017; Zhang et al., 2013). Many of the disease-linked immune-
related gene products, such as Pu.1, Trem2, CD33, and complement receptor 1, are 
expressed by microglia. In addition, recent studies identified epigenetic changes in a 
number of genes, some of them immune-related, in sporadic AD cases (De Jager et 
al., 2014; Gjoneska et al., 2015; Lunnon et al., 2014), highlighting the importance of 
epigenetic regulatory mechanisms in driving cellular dysfunction in disease.  
Since the immune system is tightly involved in the progression of neurodegenerative 
diseases, alterations of immune cells or molecules in turn change disease progression. 
This has been demonstrated by a multitude of experimental studies, in which the 
knockout or overexpression of an immune molecule modulated disease severity in 
mouse models of AD (Chakrabarty et al., 2015; Heneka et al., 2013; Jay et al., 2017; 
Masashi Kitazawa et al., 2011; Shi et al., 2011; Vom Berg et al., 2012). In summary, 
data from animal models and epidemiological and genetic data in humans implicate 
inflammation as a disease contributing component rather than a mere bystander effect 
of AD pathology. However, despite the many studies on this subject, it remains 
unclear how microglia are involved and which microglial activation states are 
beneficial or detrimental for disease progression. Our studies on the impact of 
microglial immune memory on features of cerebral β-amyloidosis will be discussed in 
chapters 2.5.2 and 2.5.3.  
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2.5 Long-lasting epigenetic microglial memory of peripheral 
inflammation modulates hallmarks of Alzheimer’s disease 
pathology 
2.5.1 Microglial longevity and its consequences 
 
In reference to: 
Microglia turnover with aging and in an Alzheimer’s model via long-term in vivo 
single-cell imaging  
Petra Füger, Jasmin K. Hefendehl, Karthik Veeraraghavalu, Ann-Christin Wendeln, 
Christine Schlosser, Ulrike Obermüller, Bettina M. Wegenast-Braun, Jonas J. Neher, 
Peter Martus, Shinichi Kohsaka, Martin Thunemann, Robert Feil, Sangram S. Sisodia, 
Angelos Skodras, Mathias Jucker (2017). Nature Neuroscience 
 
Under homeostatic conditions, microglia are uniformly distributed in the cortex, 
forming a dense, non-overlapping territorial network with their constantly moving 
ramified processes (Davalos et al., 2005; Lawson et al., 1990; Nimmerjahn et al., 
2005). Upon encountering tissue damage, microglia rapidly react with phenotypic 
changes and proliferation (Hanisch & Kettenmann, 2007). Microgliosis occurs in 
various neurological conditions (Gomez-Nicola et al., 2013; Streit et al., 1999); 
despite this, there is a paucity of knowledge on microglial turnover under homeostatic 
and disease conditions.  
Deciphering microglial maintenance is instrumental for understanding microglial 
function and dysfunction in aging, neurodegenerative disease, and following early-life 
priming. An early study using labeling with 3H-thymidine reported very low 
proliferation rates of microglia and shaped the view of microglia as very long-lived 
tissue macrophages (Lawson et al., 1992). However, estimation of the microglial 
lifetime was done indirectly by labeling DNA synthesis rather than cellular division 
(Duque & Rakic, 2011; Maurer, 1981). 
In our study, we aimed to directly observe microglial turnover by long-term in vivo 
imaging of individual microglia. To this end, we fluorescently labeled a small 
subpopulation of microglia using tamoxifen-inducible Cre-mediated recombination. 
In contrast to ectopic labeling of all microglia, where individual cells are hardly 
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distinguishable from each other, tamoxifen-inducible labeling allows fine-tuning the 
amount of recombined cells by adjusting tamoxifen dose and injection paradigm. In 
our study, we chose a tamoxifen injection paradigm that led to random recombination 
in about 2% of all microglia, thereby allowing repeated identification of the same cell 
with great certainty. Using two-photon imaging of the living mouse brain, the fate of 
individual labeled microglia was followed over longitudinally up to 16 months. While 
most microglia remained stable over time, rare events of proliferation and cellular 
death occurred. Over the course of 6 months, roughly 13% of microglia died. 
Strikingly, the same percentage of microglia appeared as newly born cells. In line 
with previous reports (Hefendehl et al., 2014), these data indicate that microglial 
numbers are largely stable during the lifespan of a mouse.  
A recent paper described spatially and temporally coupled apoptosis and proliferation 
as a mechanism for microglial network maintenance (Askew et al., 2017). However, 
in their study, newly appearing microglia were more prone to apoptotic cell death 
than the remaining microglial population; an effect we did not observe. Askew et al. 
also reported markedly higher microglial proliferation rates than previously described 
(Lawson et al., 1992) and attributed cortical microglia a lifetime of roughly 3 months. 
However, estimating the microglial turnover rate was done indirectly using 
bromodeoxyuridine (BrdU) incorporation or following labeling with viral vectors, 
which could alter the homeostatic microglial proliferation rate. In contrast, our study 
revealed low microglial proliferation rates and stable insertion of newly generated 
cells into the microglial network. From our long-term in vivo imaging data, the 
microglial lifetime in the cortex was estimated to around 29 months. A recent study, 
which was based on a genetically modified mouse model to label individual microglia 
followed by analysis of brain sections, assigned microglia a lifetime of 24 months in 
the cortex (Tay et al., 2017), comparable to our results. 
While some studies have suggested the existence of a microglial progenitor cell type 
in the brain (Bruttger et al., 2015; Elmore et al., 2014), neither our study nor the other 
recent reports (Askew et al., 2017; Tay et al., 2017) found evidence for this. Our 
long-term in vivo imaging data revealed that newly appearing microglia initially 
appeared at a distance smaller than the average inter-microglial distance to already 
existing microglial cells, and this observation was sometimes preceded by an increase 
in cell-body volume of a stable microglial cell. This indicates that new cells arise by 
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division of existing microglia. However, it remains unclear whether the newly born 
microglial cell is phenotypically similar to its chronologically older parent cell or 
acquires a different phenotype. 
Recent studies described brain region-dependent variety in microglial proliferation 
rates (Askew et al., 2017; Tay et al., 2017). In addition, region-dependent 
heterogeneity in microglial transcriptomes has been demonstrated (Grabert et al., 
2016), indicating that microglial function and turnover vary depending on local 
environment. Alterations of the brain environment in disease have been shown to 
induce marked microgliosis (Gomez-Nicola et al., 2013; Streit et al., 1999). In line 
with these findings, following the fate of individual microglia in a mouse model with 
early onset and fast progression of Aβ deposition (APPPS1 mice) revealed a 3-fold 
increase in microglial proliferation, but unaltered microglial death rates in comparison 
to imaged mice without cerebral β-amyloidosis. Surprisingly, plaque-associated 
microglia showed equivalent proliferation and death rates. In fact, increased 
microglial proliferation was solely observed in plaque-distant microglia and was 
followed by migration of the newly born cells to amyloid plaques. These data point to 
marked heterogeneity among plaque-associated microglia in APP transgenic mice 
above a certain age.  
Furthermore, our study indicates that both in health and disease the microglial 
population in an aged brain consists of microglia with varying ages. Our data reveal 
that about 50% of the microglial population persist throughout the life span of a 
healthy mouse, while the remaining microglia are of varying age and have arisen by 
cellular division. This provides an explanation for age-associated heterogeneity in 
microglial responses (Grabert et al., 2016; Hefendehl et al., 2014; Streit et al., 2004) 
and highlights the importance of single-cell profiling studies. Furthermore, their long 
lifetime explains the previously described long-lasting alterations of microglial 
function after early-life priming (Krstic et al., 2012; Perry & Holmes, 2014). Of note, 
other macrophage populations (perivascular and meningeal) in the CNS have recently 
been shown to resemble microglia in their development from embryonic 
hematopoietic precursors, a very limited turnover from peripheral monocytes, and an 
extremely long lifetime (Goldmann et al., 2016; Prinz et al., 2017). It remains to be 
determined whether these other long-lived resident macrophage populations also 
contribute to aging- or priming-related changes in the brain.  
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2.5.2 Modulation of cerebral β-amyloidosis by epigenetically encoded 
microglial memory after systemic inflammation 
 
In reference to: 
Innate immune memory in the brain shapes neurological disease hallmarks 
Ann-Christin Wendeln*, Karoline Degenhardt*, Lalit Kaurani, Michael Gertig, 
Thomas Ulas, Gaurav Jain, Jessica Wagner, Lisa M. Häsler, Katleen Wild, Angelos 
Skodras, Thomas Blank, Ori Staszewski, Moumita Datta, Tonatiuh Pena Centeno, 
Vincenzo Capece, Md. Rezaul Islam, Cemil Kerimoglu, Matthias Staufenbiel, 
Joachim L. Schultze, Marc Beyer, Marco Prinz, Mathias Jucker, André Fischer, and 
Jonas J. Neher (2018). *contributed equally.  
 
With all cells possessing the same genetic information, epigenetic regulation of 
transcriptional programs is required for adaptation of specific cell fates. Epigenetics 
refers to all modifications of DNA or histones that occur without altering the genetic 
sequence. Instead, epigenetic modifications alter chromatin packaging and control 
accessibility of DNA-binding factors to regulatory elements (Jenuwein & Allis, 
2001). Thereby, specific histone modifications in promoter regions or in distant cis-
regulatory elements, so called enhancers, critically control gene expression (Ivashkiv, 
2013), with chromatin modifications at enhancers reflecting cellular transcriptional 
profiles better than epigenetic modifications at promoter regions (Heintzman et al., 
2009). In any given cell, only a small subset of all genome-wide enhancers is active at 
a given time and subsequently determines gene expression profiles. During 
development, lineage-determining transcription factors (LDTFs) prime a subset of 
enhancers. In turn, signal-dependent transcription factors (SDTFs) activated in 
response to cues of the local environment bind to primed enhancers to initiate cell-
type specific gene expression. Thereby, lineage- and tissue-specific regulatory 
networks are integrated to epigenetically determine cellular identity and function 
(Glass & Natoli, 2015; Heinz et al., 2015).  
While microglia have a distinct ontogeny from tissue-resident macrophage 
populations in other organs, they share common functions and developmental 
features, such as the dependency on the LDTF Pu.1 (Kierdorf et al., 2013; Smith et 
al., 2013). However, due to the major influence of the CNS environment, microglial 
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enhancer landscape and gene expression differ in several hundred genes from other 
macrophages (Gautier et al., 2012; Gosselin et al., 2014; Lavin et al., 2014). 
Interestingly, transferring macrophages to another tissue environment reshaped their 
active enhancer and gene expression profile to a certain extent to resemble the 
resident macrophage population (Lavin et al., 2014), confirming that external stimuli 
in the tissue environment exert a major influence on cellular identity via SDTFs.  
Epigenetic reprogramming has previously been implied as the basis for innate 
immune memory, since training and tolerance led to stable epigenetic histone 
modifications and transcriptional reprogramming in monocytes and macrophages in 
vitro (Saeed et al., 2014). So far, innate immune memory has been described in vitro 
and in vivo for up to 3 months in circulating monocytes (Kleinnijenhuis et al., 2012; 
Saeed et al., 2014), but whether it exists in the brain remains completely unknown. In 
our study, we therefore tested whether innate immune memory occurs in microglia 
and influences neurological disease. We found that peripheral immune stimulation 
epigenetically reprogrammed microglia and was sufficient to alter much later 
occurring neurological disease hallmarks. Since microglia are long-lived cells (see 
chapter 2.5.1), it is possible that microglial immune memory persists for their entire 
lifetime and thereby exerts long-lasting effects on brain homeostasis and pathology. 
It is well established that peripheral inflammatory events are transduced to the brain 
(Cunningham et al., 2009; Perry et al., 2007; Qin et al., 2007). In our study, we 
therefore used daily peripheral application of LPS for up to four consecutive days to 
induce systemic inflammation and tested whether acute immune memory effects were 
evident in the brain. A single peripheral injection of LPS (1xLPS) led to acute 
cytokine release in the periphery and brain. In the brain, repeated exposure to LPS on 
the following day (2xLPS) resulted in a much stronger release of several pro-
inflammatory cytokines (such as IL-1β, TNF-α, IL-6, and IL-12) compared to the first 
LPS injection, indicative of training. This massive cytokine release upon training was 
abrogated in microglia-specific knockout mice (of Tak1 or Hdac1/2), indicating that 
immune training in the brain is predominantly mediated by microglia. Training was 
accompanied by morphological changes of microglia, suggesting that microglia are 
the cells capable of immune memory formation in the brain. 
In contrast, training was not detectable in the periphery, since pro-inflammatory 
cytokine release in the serum was diminished upon the second LPS injection, and was 
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even further reduced with the following daily LPS injections (3xLPS and 4xLPS). 
However, the levels of the anti-inflammatory cytokine IL-10 remained high with 
repeated LPS injections in the serum, indicating induction of tolerance in the 
periphery. In contrast to immune training observed after 2xLPS in the brain, 3x and 
4xLPS led to a strong reduction in pro-inflammatory cytokine release while IL-10 
levels remained elevated, demonstrating that repeated LPS exposure (3x and 4xLPS) 
also caused immune tolerance in the brain. 
These results demonstrate that dependent on the number of LPS injections acute 
immune training and tolerance are inducible in the brain (Figure 3). In line with our 
results, dose and time-dependency of training and tolerance have previously been 
described for LPS. While low doses of LPS induced training in macrophages (Deng et 
al., 2013; Zhang & Morrison, 1993), high doses resulted in endotoxin tolerance in 
vitro and in vivo (Beeson & Roberts, 1947; del Fresno et al., 2009). While we used 
one dose of LPS in our study, our results demonstrate dependency on the number of 
applications, with the first injection inducing training subsequently, and repeated 
injections (3x and 4xLPS) on consecutive days leading to tolerance. 
In line with results from others (Banks & Robinson, 2010), LPS did not enter the 
brain of mice, suggesting other ways of signal transduction to the brain, such as 
cytokine transport across the intact blood-brain barrier (BBB) or cytokine secretion by 
endothelial cells of the BBB (Quan & Banks, 2007). A study on the protective effects 
of IL-1β pretreatment on lethal infection in mice suggested that certain cytokines can 
induce training by themselves (van der Meer et al., 1988). In addition, several recent 
studies assigned IL-1β a crucial role in mediating trained immunity in the periphery 
(Arts et al., 2018; Christ et al., 2018; Mitroulis et al., 2018). In our study, we 
demonstrate that peripheral injection of the cytokines TNF-α and IL-10 also gave rise 
to innate immune memory effects in the brain in response to LPS stimulation 4 weeks 
later. Interestingly, while a low dose injection of TNF-α elicited training, application 
of high dose TNF-α caused tolerance, highlighting the importance of the dose also in 
shaping innate immune memory in the brain. Furthermore, tolerance was induced 
after repeated application of the anti-inflammatory cytokine IL-10, suggesting that 
multiple cytokines are able to induce innate immune memory in the brain. 
As acute immune memory effects were evident in the brain after peripheral immune 
stimulation, we wondered whether immune training and tolerance exert long-lasting 
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effects on the brain’s immune response and thereby influence later occurring 
neuropathology. Since a single peripheral injection of LPS (1xLPS) induced immune 
training upon subsequent re-exposure to LPS, and four LPS injections (4xLPS) led to 
tolerance in the brain, we tested the effects of 1xLPS as a training stimulus or 4xLPS 
as a tolerizing stimulus on disease pathology. Peripheral immune stimulation of pre-
depositing APP23 mice with 1xLPS or 4xLPS modified hallmarks of cerebral β-
amyloidosis 6 months later, i.e. at an early stage of disease pathology. In 9 months old 
APP23 mice, animals that were treated at 3 months of age with 1xLPS had increased 
plaque load and Aβ levels, while animals treated with 4xLPS showed decreased Aβ 
pathology. A differential immune state as indicated by changes in cytokine levels (i.e. 
reduced IL-10 levels in 1xLPS treated APP23 mice and reduced IL-1β levels in 
4xLPS treated APP23 mice) was evident in the brain, but not the periphery, of 
immune stimulated 9 months old APP23 animals (Figure 3). These data highlight that 
immunological memory in the periphery was by far shorter lived compared to the 
brain, an effect that can be explained by the differing lifetimes of myeloid cell 
populations (a period of days for circulating monocytes versus many months for 
microglia). Since changes in the brain’s immune state were absent in 9 months old 
immune stimulated wildtype animals, a second stimulus (e.g. Aβ deposition in APP23 
mice) within a certain time frame of the first immune stimulus seems to be required to 
observe a differential immune response. In line with this, analysis of the microglial 
enhancer repertoire revealed differences in enhancer activation in response to 
peripheral immune stimulation in wildtype compared to APP23 animals. 
Previous studies suggested a stepwise model of macrophage enhancer activation in 
innate immune memory (Netea et al., 2016; Ostuni et al., 2013). An immune stimulus 
elicits gene expression changes, which are epigenetically encoded in histone 
modifications on promoters and enhancers. Large scale epigenomic studies revealed 
that methylation and acetylation of particular histone residues are either constitutive 
or activity-dependent marks indicative of particular gene elements such as exons, 
introns, enhancers, and promoters (Jenuwein & Allis, 2001; Zhou et al., 2011). In 
particular, acetylation at lysine 27 on histone 3 (H3K27ac) occurs in enhancers and 
promoters that are activated by SDTFs in response to an immune stimulus, changing 
chromatin structure to an open state and initiating gene transcription. A subset of 
enhancers, termed latent enhancers, is believed to form the epigenetic basis of innate 
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immune memory (Netea et al., 2016; Saeed et al., 2014). Latent enhancers are distal 
regulatory elements that are epigenetically unmarked or marked at low levels in 
unstimulated cells, but gain histone modifications characteristic of enhancers, such as 
monomethylation at lysine 4 on histone 3 (H3K4me1), in response to specific stimuli 
(Netea et al., 2016; Shlyueva et al., 2014). Latent enhancers activated by SDTFs in 
response to an immune stimulus thereupon gain the epigenetic modifications 
H3K27ac and H3K4me1 (Figure 2). Once the acute immune reaction has been 
resolved, which is in the experimental setup in this study less than 24 hours after the 
last LPS injection, enhancers and promoters are turned off and lose H3K27ac. 
However, some of the previously active latent enhancers retain H3K4me1 as a sign of 
their recent activity and thereupon stay in a primed state. These primed enhancers are 
not yet active but are associated with open chromatin structure and thus can undergo a 
stronger activation upon restimulation (Netea et al., 2016; Shlyueva et al., 2014). 
Upon a secondary immune stimulus, such as the deposition of Aβ, a subset of 
H3K4me1-marked primed enhancers are reactivated and regain H3K27ac, leading to 
adapted transcriptional changes in comparison to the naïve immune reaction, 
indicative of innate immune memory (Figure 2).  
In line with this concept, peripheral immune stimulation with LPS led to changes in 
the microglial primed enhancer repertoire (based on differential H3K4me1 levels) 
6 months later in wildtype and APP23 animals, while no changes in primed enhancers 
occurred in response to cerebral β-amyloidosis itself. Both in wildtype and APP mice, 
H3K4me1 levels of microglial enhancers differed significantly between all treatment 
groups, demonstrating that primed enhancers are primarily established in response to 
peripheral immune stimulation. In comparison to 4xLPS treated wildtype mice, the 
thyroid hormone signaling pathway, including an enhancer of hypoxia-inducible 
factor (HIF) 1-α, was enriched in microglial primed enhancers after 1xLPS treatment 
in wildtype mice. These pathways are central regulators of metabolism and activity of 
innate immune cells (Weichhart et al., 2015). The HIF1-α signaling pathway was also 
enriched in microglial primed enhancers from 1xLPS versus 4xLPS treated APP 
mice, in line with the description of HIF1-α as a central regulator of macrophage 
function (Cramer et al., 2003) and immune training in monocytes (Cheng et al., 
2014).  
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Most changes in microglial primed enhancer repertoire occurred after 4xLPS 
treatment both in wildtype and APP23 mice, confirming the proposed view of 
endotoxin tolerance as an alternative activation state of the immune system rather 
than complete silencing (Foster et al., 2007; Shalova et al., 2015). Primed enhancers 
from 4xLPS treated mice were enriched in pathways related to phagocytosis. Of note, 
the vast majority of primed enhancers established by 4xLPS did not gain H3K27ac, 
possibly due to the presence of additional repressive histone modifications. In support 
of this hypothesis, tolerance initiating LPS preconditioning of microglia revealed 
reduced deposition of activating histone marks and increased amounts of repressive 
histone marks on pro-inflammatory IL-1β gene promoter (Schaafsma et al., 2015).  
In line with the idea that primed enhancers gain H327ac only upon secondary 
stimulation, such as the deposition of Aβ that in turn activates microglia, differential 
enhancer activation occurred predominantly in APP23 and to a lesser extent in 
wildtype mice after peripheral immune stimulation. Of note, our analysis revealed 
changes in microglial active enhancers in response to cerebral β-amyloidosis itself, 
including enhancer activation of mechanistic target of rapamycin (mTOR), whose 
dysregulation has been implicated in AD (Wang et al., 2014). Furthermore, active 
enhancers were enriched in the thyroid hormone signaling pathway, including an 
active enhancer of HIF1-α, in APP23 animals.  
In line with the description of HIF1-α as an essential mediator of training in 
monocytes (Cheng et al., 2014) and reflecting the establishment of primed enhancers, 
HIF1-α signaling pathway was enriched after 1xLPS treatment in microglial active 
enhancers in APP23 mice. Both mTOR and HIF1-α regulate trained immunity by 
controlling the metabolic state of immune cells, leading to a shift towards aerobic 
glycolysis upon training of monocytes (Bekkering et al., 2018; Cheng et al., 2014) . 
In contrast, microglial active enhancers of 4xLPS treated mice were enriched for Ras-
related protein 1 (Rap1) signaling, a pathway involved in phagocytosis (Chung et al., 
2008), again reflecting the established primed enhancers. Microglial active enhancers 
of 1xLPS treated mice showed enrichment of many inflammatory pathways in 
comparison to 4xLPS, in line with a previous study on the epigenetic state of 
endotoxin tolerant macrophages (Foster et al., 2007). In summary, our results imply 
that differential modulation of neuropathology is at least partly mediated by long-term 
changes in microglial function based on epigenetic reprogramming, in line with 
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previous reports on the epigenetic basis of innate immune memory (Saeed et al., 
2014). 
 
Figure 2: Epigenetic basis of innate immune memory. Peripheral immune stimulation 
activates SDTFs and leads to deposition of H3K27ac at a subset of enhancers, thereby 
opening chromatin structure and initiating gene transcription. After cessation of the immune 
stimulus, enhancers are turned off and loose H3K27ac; however, primed enhancers retain 
H3K4me1 as an epigenetic mark of their previous activity. A secondary immune stimulus, 
e.g. the deposition of Aβ, activates a subset of primed H3K4me1-marked enhancers and 
thereby elicits an adapted immune reaction with altered gene expression in comparison to the 
naïve immune response. Based on Netea et al., 2016.  
 
 24 
Since enhancers are critical regulators of transcriptional activity (Heintzman et al., 
2009; Ivashkiv, 2013), epigenetic alterations in active enhancers should be reflected 
in gene expression levels. Indeed, there was a significant concordance between 
alterations in H3K27ac levels and the direction of change in the expression of the 
nearest gene in sorted microglia. Furthermore, weighted gene correlation network 
analysis (WGCNA) revealed striking similarities to epigenetic changes. WGCNA 
identified a module enriched for HIF1-α signaling, for which gene expression 
correlated strongly with microglia from 1xLPS treated APP23 mice, but not with 
microglia from 4xLPS treated APP23 mice. In addition, HIF1-α protein levels were 
increased in plaque-associated microglia and further upregulated in 1xLPS treated 
APP23 mice. Interestingly, other genes that have been genetically linked to AD risk 
appeared in the same module as HIF1-α, indicating that HIF1-α signaling may indeed 
represent a detrimental event in AD pathology. 
Upon immune cell activation, cellular energy and biosynthesis pathways need to be 
repurposed to meet increased energy demands and provide necessary building blocks. 
Changes in the contribution of metabolic pathways to energy production and 
biosynthesis have been linked to immune cell polarization (Galván-Peña & O’Neill, 
2014; O’Neill & Pearce, 2016; Pearce & Pearce, 2013) and innate immune memory 
(Arts et al., 2016a; Bekkering et al., 2018; Cheng et al., 2014; Saeed et al., 2014). In 
pro-inflammatory activated macrophages in vitro, mitochondria shift from adenosine 
triphosphate (ATP) production to reactive oxygen species (ROS) generation, enabling 
mitochondria to maintain a high membrane potential (Mills et al., 2016). In turn, ROS 
stabilize and activate HIF1-α, promoting energy production by glycolysis, leading to 
increased lactate release, and altering inflammatory gene expression (Hamanaka et 
al., 2016; Mills et al., 2016). In β-glucan trained monocytes, a mTOR- and HIF1-α-
dependent shift towards glycolysis occurred in vitro (Cheng et al., 2014), resembling 
metabolic reprogramming described in LPS activated macrophages in vitro (Tannahill 
et al., 2013). 
In our study, WGCNA identified a module enriched in genes of the glycolytic 
pathway. Indeed, in line with increased HIF1-α activity, microglial gene expression in 
this module was increased in microglia from APP versus wildtype control mice and 
showed further upregulation in 1xLPS treated APP animals. Functional analysis of 
sorted microglia confirmed that microglia from 1xLPS treated mice possessed an 
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increased mitochondrial membrane potential, which correlated with microglial lactate 
release as readout of glycolytic activity. In summary, increased HIF1-α activity and a 
metabolic switch to glycolysis occurred in response to cerebral β-amyloidosis and was 
enhanced by immune training in microglia (Figure 3), confirming metabolic 
reprogramming in trained immunity in vivo. 
In line with enhancer modification, WGCNA revealed increased expression of a 
module enriched in phagocytic and endocytic pathways and Rap1 signaling in 
microglia from 4xLPS treated mice. Indeed, tolerized microglia contained higher 
amounts of Aβ, confirming epigenetic and gene expression data. This, together with 
the reduced plaque load in 4xLPS treated mice, suggests that microglia change to a 
beneficial phenotype associated with increased Aβ phagocytosis after induction of 
tolerance (Figure 3). 
Figure 3: Acute and long-lasting effects of peripheral immune stimulation in APP23 
mice. A single peripheral LPS injection at 3 months of age (1xLPS) induces immune training 
subsequently, while repeated peripheral LPS application (4xLPS) causes tolerance in the 
brain. In immune stimulated APP23 mice, Aβ deposition starts at 6 months of age and acts as 
a secondary immune stimulus. At 9 months of age, differential modulation of Aβ pathology 
and the brain’s immune response is apparent after 1xLPS and 4xLPS stimulation. Immune 
memory effects are based on epigenetic reprogramming of microglia, thereby altering their 
gene expression profile and impacting on microglial function.  
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The described changes in global microglial enhancer and transcriptional landscape are 
likely driven by alterations in a subset of microglia, since differences in protein 
expression, e.g. for HIF1- α, were mainly restricted to plaque-associated cells. 
Recently, heterogeneity of microglia was confirmed based on single-cell 
transcriptional profiling (Keren-Shaul et al., 2017; Korin et al., 2017; Mathys et al., 
2017). In addition, subtypes of microglia with pathology-specific distinct molecular 
signatures (termed disease-associated microglia and microglial neurodegenerative 
phenotype) have been described (Keren-Shaul et al., 2017; Krasemann et al., 2017). 
Our work indicates that training and tolerance are able to modulate disease-induced 
alterations of microglial gene expression and function in a differential fashion. In 
addition to modulation of cerebral β-amyloidosis after peripheral immune stimulation, 
1xLPS and 4xLPS treatment also altered neuropathological features of stroke, 
indicating that modification of disease pathology after epigenetic microglial 
reprogramming in response to systemic inflammation is not specific to the context of 
cerebral β-amyloidosis. Since microglia play a role in virtually all neurological 
diseases investigated so far, microglial immune memory of previous inflammatory 
events could be an essential modifier of disease pathogenesis in many other 
circumstances. It remains to be determined, which stimuli (systemic or local) induce 
microglial epigenetic reprogramming and how long this persists under different 
conditions in the tissue environment.  
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2.5.3 Modulation of amyloid plaque structure and neuronal damage 
through long-term microglial changes after systemic inflammation  
 
In reference to: 
Systemic inflammation induces long-term modulation of amyloid plaque 
morphology and neuronal damage in a mouse model of Alzheimer’s disease 
Ann-Christin Wendeln, Angelos Skodras, Natalie Beschorner, Peter Nilsson, Mathias 
Jucker, Jonas Neher 
 
Recently, a previously unappreciated role of microglia in amyloid plaque compaction 
has been described. Microglia strongly accumulate around Aβ plaques and closely 
interact with them (Itagaki et al., 1989), but how intimate the interaction between 
microglia and amyloid plaques is has only recently emerged. In AD, microglia are not 
merely passive bystanders around plaques but can actively clear them by 
phagocytosis, a process that increases after immunotherapy against Aβ (D’Andrea et 
al., 2004; Fu et al., 2010; Lai & McLaurin, 2012). In addition, recent studies 
demonstrated that microglial processes form a tight barrier around amyloid plaques, 
thereby compacting the toxic Aβ species and reducing their interaction with the brain 
environment (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016). In mouse 
models of cerebral β-amyloidosis, neuronal damage occurs in the form of dystrophic 
neurites and axonal damage around Aβ plaques (Calhoun et al., 1998; Sturchler-
Pierrat & Staufenbiel, 2000). By forming a barrier around amyloid deposits, microglia 
reduce amyloid-associated neuronal damage and protect surrounding cells by 
shielding toxic Aβ species.   
In AD, there is considerable heterogeneity in plaque structures, ranging from dense 
core and compact (Thioflavin S positive) to diffuse and filamentous amyloid deposits 
(D’Andrea et al., 2004; Yuan et al., 2016). Furthermore, microglial interaction with 
plaques differs, with dense plaques showing strong clustering of microglial processes 
and diffuse plaques having much less microglial coverage (Condello et al., 2015; 
Itagaki et al., 1989). Importantly, modulation of the microglial barrier function by 
genetic deletion of CX3CR1 or Trem2 or in response to anti-Aβ immunization 
resulted in structurally altered amyloid plaques (Condello et al., 2015; Wang et al., 
2016; Yuan et al., 2016). In turn, plaque structure influenced the amount of associated 
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neuritic dystrophy, with recent studies demonstrating an association between reduced 
compaction of plaques and increased neuronal damage (Condello et al., 2015; Wang 
et al., 2016; Yuan et al., 2016). These studies imply another previously unappreciated 
microglial function in the modulation of AD pathology.  
As discussed in chapter 2.5.2, we provided evidence for long-lasting alterations in 
microglial function after systemic inflammation. These microglial changes occurring 
in response to single (1xLPS) or repeated (4xLPS) peripheral LPS stimulation were 
sufficient to differentially modulate Aβ plaque load at an early stage of pathology in 
9 months old APP23 mice. In this follow-up study, we characterized the long-term 
effects of systemic inflammation, induced by 1xLPS or 4xLPS treatment at young 
adult age, on the structure of amyloid deposits and associated neuronal damage. Using 
staining with luminescent conjugated oligothiophenes (LCOs) followed by spectral 
imaging, we showed that 1xLPS and 4xLPS treatment at 3 months of age both caused 
structural changes in much later formed amyloid plaques in APP23 animals.  
LCOs are fluorescent dyes showing shifts in their emission spectrum upon binding to 
different amyloid structures (Aslund et al., 2009; Klingstedt et al., 2011). Costaining 
with two LCOs, quadro-formyl thiophene acetic acid (qFTAA) and hepta-formyl 
thiophene acetic acid (hFTAA), has previously been used to discriminate between 
different plaque structures in human AD cases and demonstrated intra- and inter-
individual variability in plaque morphologies (Rasmussen et al., 2017). While qFTAA 
resembles Thioflavin S in its binding affinity for mature Aβ fibrils in the dense core 
of plaques, hFTAA stains both immature and mature fibrillar forms (Klingstedt et al., 
2011). The ratio of emission intensities at the respective maxima of qFTAA and 
hFTAA provides a useful readout for the spectral distinction of different amyloid 
plaque structures (Rasmussen et al., 2017).   
In this study, we analyzed 12 months old APP23 animals treated with 1xLPS or 
4xLPS to induce training or tolerance in the brain, respectively, at 3 months of age. 
Peripheral stimulation with both 1xLPS and 4xLPS altered amyloid structure in 
comparison to control animals: Control animals showed a significantly higher 
proportion of dense core plaques (qFTAA- and hFTAA-positive), while diffuse 
amyloid deposits (qFTAA-negative) predominated in LPS treated animals. In line 
with previous studies (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016), 
less compact plaques induced by 1xLPS and 4xLPS were associated with increased 
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neuronal damage. In fact, neuronal damage around single plaques was not only 
significantly influenced by plaque size but also by plaque structure (as measured by 
the core qFTAA/hFTAA binding ratio).  
Despite the differences in plaque structure, total plaque load did not differ among 
treatment groups, indicating that the continuous strong overproduction of Aβ in this 
mouse model overrides the effects of peripheral immune stimulation on Aβ load with 
time. Strikingly, alterations of plaque-associated microglia were still present in LPS 
treated 12 months old APP23 mice, in line with the hypothesis that microglia may be 
mediating the observed changes in amyloid conformation.  
We first analyzed microglial numbers and found no alterations in the overall number 
of microglia; however, the number of plaque-associated microglia was reduced in 
4xLPS treated animals, possibly due to altered migration or turnover of tolerant 
microglia. No alterations in the amount of plaque-associated astrocytes were found 
after LPS stimulation in 12 months old APP23 mice. Since microglia can compact 
amyloid plaques (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016), a 
reduction in the number of microglia and concomitantly the amount of microglial 
processes encompassing the plaque could result in impairment of the microglial 
barrier function and thereby alter amyloid plaque structure.  
We have previously observed increased Aβ phagocytosis in 4xLPS treated microglia 
at an earlier stage of pathology (see chapter 2.5.2). Since microglial phagocytosis 
could contribute to the restructuring of amyloid plaques, we assessed CD68 
expression, which marks active phagolysosomes (Rabinowitz et al., 1992). Microglial 
CD68 expression and colocalization with amyloid plaques was reduced in 1xLPS 
treated animals in comparison to controls, indicating a reduction in phagocytic 
activity of 1xLPS but not 4xLPS treated microglia. 
Trem2 has previously been linked to microglial barrier function and structural 
compaction of amyloid plaques (Wang et al., 2016; Yuan et al., 2016). Analysis of 
Trem2 expression revealed, similar to CD68, a reduction in microglial expression and 
colocalization with amyloid plaques in 1xLPS treated animals. Furthermore, 1xLPS 
treated animals depicted an altered immune state in the brain with elevated pro-
inflammatory cytokine levels (such as IL-6, IL-12, and IFN-γ). Together, these data 
demonstrate a shift in the phenotype of plaque-associated microglia after 1xLPS 
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treatment and indicate that alterations in the microglial phenotype can change amyloid 
plaque structure.  
In summary, this study suggests that both number and phenotype of plaque-associated 
microglia influence amyloid structure. Modulation of amyloid plaque structure after 
1xLPS and 4xLPS treatment occurred through different microglia-mediated 
mechanisms, demonstrating that the differential effects of training and tolerance 
persisted even longer than we had previously shown (Wendeln & Degenhardt et al., 
2018). Furthermore, this study highlights the complex interaction between the 
immune system and amyloid deposits and its influence on disease progression. While 
at early stages of pathology, induction of tolerance by peripheral 4xLPS stimulation 
reduced cerebral β-amyloidosis while training with 1xLPS increased Aβ pathology, 
these effects on plaque load diminished at a later stage of pathology. Instead, 
exacerbated neuronal damage was evident around structurally altered amyloid plaques 
in both treatment groups. Similar to the stage-dependent effects of tolerance, such a 
biphasic influence on Aβ pathology has previously been described for Trem2 
knockout mice (Jay et al., 2015, 2017).  
While at early stages of Aβ pathology (before 10 months in APP23 animals), only 
immature Aβ fibrils with a binding affinity for hFTAA are present, the amount of 
plaques with dense cores (qFTAA-positive) increases as Aβ fibrils mature and 
amyloid plaques grow in size (Nyström et al., 2013). Interestingly, binding of qFTAA 
reaches a plateau around 18 months of age and decreases afterwards, indicating that 
structural rearrangement takes place in amyloid plaques in aged animals. In line with 
this finding, microglial barrier function was impaired in aged mice, resulting in less 
compact plaques with more associated neuritic dystrophy (Condello et al., 2015). 
Thus, similar to the diminishment of homeostatic and injury-induced microglial 
activity with age (Hefendehl et al., 2014; Lynch et al., 2010; Yu et al., 2002), 
microglial coverage of amyloid plaques seems to be reduced in aged mice and might 
therefore account for the described differences in qFTAA binding over the course of 
aging.  
In summary, this study confirms that systemic inflammation causes long-lasting 
alterations in microglial function that subsequently influence amyloid plaque 
structure. In 12 months old APP23 animals, both 1x and 4xLPS treatment (albeit 
through different mechanisms) caused impairments of microglial barrier function, 
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hence leading to altered amyloid plaque structures associated with increased neuronal 
damage. These results confirm the protective nature of the microglial barrier around 
amyloid plaques and demonstrate that this function can be permanently impaired by 
systemic inflammatory events occurring much earlier in life. Thereby, long-lasting 
alterations of the microglial barrier function represent another mechanism modulating 
neurological disease progression. 
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2.6 Concluding remarks and outlook 
In this thesis, an in-depth analysis of microglial lifetime, immune memory, and its 
consequences for disease was presented. Knowledge of the microglial turnover is 
essential for the interpretation of innate immune memory effects, since the 
transmission of epigenetic modifications during cell division is still under 
investigation. Inheritance has been described for different epigenetic modifications; 
however, the mechanisms behind removal and persistence of certain chromatin marks 
remain elusive. While DNA methylation can be reestablished after DNA replication 
with high fidelity, it is less clear which histone modifications are inherited during cell 
division and how they are established (Probst et al., 2009). Therefore, it remains 
unclear, whether chronologically younger cells are also biologically younger, or 
whether they retain the epigenetic marks and age-induced changes of their respective 
parent cell.  
We investigated microglial lifetime and turnover under homeostatic conditions and in 
a mouse model with cerebral β-amyloidosis by imaging individual microglia. Our 
results demonstrated very limited turnover of the microglial population and assigned 
cortical microglia a lifetime of many months in mice. At any given age, animals will 
thus contain a heterogeneous mixture of microglia of varying individual ages. Bulk 
sequencing studies, especially of aged mice, will therefore profile microglia with 
variable ages and unclear inheritance of chromatin marks, highlighting the importance 
for future single-cell studies across different ages under homeostatic and disease 
conditions. Since about half of the microglial population persists for the entire 
lifespan of mice, age-related cellular senescence might contribute to the development 
of neurological diseases. Indeed, homeostatic functions of microglia decline in aged 
mice (Hefendehl et al., 2014), thereby predisposing to disease onset. Even in a mouse 
model of cerebral β-amyloidosis, where microglial proliferation was increased, a 
considerable proportion of microglia persist for the entire lifespan of mice, indicating 
that microglial senescence could occur even under disease conditions with increased 
turnover.  
Translation of our findings about the microglia lifetime to the human brain remains 
uncertain. However, other cell types such as neurons and oligodendrocytes have been 
shown to persist in the brain throughout the human lifespan (Frisén, 2016). 
Furthermore, a heterogeneous microglial population with senescent cells has also 
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been described in the aged human brain (Streit et al., 2004; Streit et al., 2009), 
indicating that microglia in humans might also be of varying ages, with some possibly 
persisting throughout the entire lifespan. Preliminary studies on two cancer patients 
suggest (based on IdU labeling and 14C measurements) that human microglia renew at 
a median rate of 28% per year (Réu et al., 2017). Of note, human microglia appeared 
heterogeneous in their individual age, with some being more than two decades old 
(Réu et al., 2017). Further studies in a higher number of subjects will provide 
additional evidence on the turnover rate and mechanisms of microglial maintenance in 
humans compared to mice.  
Our data demonstrating a microglial lifetime of many months in mice render 
microglia suitable candidates for the study of innate immune memory, since they are 
susceptible to long-lasting alterations in their function after immune stimulation. 
Using repeated peripheral administration of LPS, we showed acute training and 
tolerance effects in the brain of mice, dependent on the number of LPS injections. In 
our study, tolerance was induced with repeated LPS injections subsequent to training; 
however, with this setup it remained unclear whether a massive immune reaction such 
as immune training is required for subsequent formation of tolerance. Dependency on 
mTOR- and HIF1-α-mediated induction of glycolysis has been shown for training in 
monocytes (Cheng et al., 2014); however, whether this applies to microglia remains 
unknown. Microglia-specific deletion of mTOR or HIF1-α will specify their role in 
the induction of acute training and tolerance effects in this cell type. In addition, a 
metabolic switch from glycolysis towards fatty acid oxidation, which predominates in 
endotoxin tolerant cells, has been described for the transition from the early phase of 
an acute immune response to the later phase (T.F. Liu et al., 2012). It remains to be 
determined whether metabolic reprogramming also accompanies the acute transition 
from training to tolerance.  
Our study provided evidence that TNF-α and IL-10 also elicit immune memory 
effects in the brain after peripheral application. Interestingly, a low dose of TNF-α 
resulted in immune training, while a high dose caused tolerance. This suggests, in line 
with the induction of tolerance after repeated LPS exposure, that a repeated or high 
dose application of a pro-inflammatory stimulus is sufficient to induce immune 
tolerance, while a single or low dose stimulus preferentially gives rise to training. 
Future studies investigating several doses of the same stimulus will reveal details 
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about the dose-dependency of innate immune memory effects. Interestingly, 
application of the anti-inflammatory cytokine IL-10 also elicited immune tolerance, 
demonstrating that tolerance is not solely induced following a strong pro-
inflammatory immune response. Future studies involving peripheral application of 
different pro- and anti-inflammatory cytokines will demonstrate which other 
cytokines induce training and tolerance in the brain, and whether they converge on 
similar signaling pathways. Importantly, any infection in the body results in release of 
a diverse array of cytokines, allowing for the possibility that innate immune memory 
in the brain could occur in response to a wide range of inflammatory events. 
We demonstrated modulation of pathology in stroke and in cerebral β-amyloidosis 
months after induction of training and tolerance in the brain by peripheral immune 
stimulation. Changes in pathology were accompanied by differing immune states in 
the brain and altered epigenetic and transcriptional profiles of microglia. Similar to 
the previously described epigenetic basis of innate immune memory (Netea et al., 
2016), differential enhancer activation in microglia also required two stimuli. In our 
study, enhancers were activated by peripheral immune stimulation and stayed in a 
primed state until reactivated upon deposition of Aβ. So far, it is unclear how long 
enhancers stay primed in response to an immune stimulus; therefore the maximal 
latency between the first and second stimulus to elicit differential enhancer activation 
in comparison to the naïve reaction remains to be determined. In addition, it is unclear 
whether newly generated microglia retain epigenetic marks of immune memory, 
potentially resulting in fading of memory of the priming stimulus over time. Long-
term studies employing peripheral immune stimulation at young ages with subsequent 
analysis of aged mice will determine how long-lasting microglial immune memory is, 
and whether it also influences age-related physiological changes.  
Priming of innate immune cells has been described to confer cross-protection against 
a range of pathogens (Moret & Siva-Jothy, 2003; Netea et al., 2011; Pham et al., 
2007); however, the mechanisms and extent of this cross-protection remain unknown. 
At the present time, the nature of the secondary stimuli that elicit immune memory 
effects and the extent of their overlap in signaling pathways with the priming stimulus 
are unknown. In our study, immune memory of peripheral immune stimulation 
elicited differential effects on more than one disease process (chronic Aβ deposition 
 35 
and stroke), but it remains to be resolved which particular circumstances elicit 
immune memory effects. 
Analysis of the microglial enhancer and transcriptional landscape in immune-
stimulated mice with cerebral β-amyloidosis revealed differential expression of 
metabolic pathways, which have previously been implicated in innate immune 
memory (Bekkering et al., 2018; Cheng et al., 2014; Saeed et al., 2014), after training 
and tolerance. Increased HIF1-α activity and a metabolic switch to glycolysis 
occurred in microglia in response to cerebral β-amyloidosis and were enhanced by 
immune training, in line with previous studies (Ip et al., 2017; Mills et al., 2016). 
However, the exact nature of the metabolic pathways involved in the response of 
tolerized microglia remains unknown. Metabolic rewiring upon immune cell 
activation is dependent on several factors such as stimulus and tissue environment, 
thereby creating unique metabolic signatures in different inflammatory conditions 
(Stienstra et al., 2017). Whereas LPS stimulation of myeloid cells in vitro induced a 
switch from oxidative phosphorylation towards aerobic glycolysis (Palsson-
McDermott & O’Neill, 2013; Rodriguez-Prados et al., 2010; Stienstra et al., 2017), 
stimulation with other TLR ligands promoted both glycolysis and oxidative 
phosphorylation in monocytes in vitro (Lachmandas et al., 2016). While many pro-
inflammatory stimuli enhanced the glycolytic rate of myeloid cells (Everts et al., 
2014; Mills et al., 2016; Stienstra et al., 2017), anti-inflammatory effects of IL-10 
were shown to be mediated by downregulation of mTOR and a metabolic shift 
towards oxidative phosphorylation in macrophages (Ip et al., 2017). In addition, a 
metabolic profile with predominating oxidative phosphorylation has been linked to 
phagocytic activity (Reiss & Roos, 1978), which was increased in tolerized microglia, 
implicating metabolic rewiring possibly also in other immune cell functions. While 
the acute hyperinflammatory phase in sepsis was associated with increased glycolytic 
rates in blood leukocytes (Haimovich et al., 2010), mTOR signaling and glycolysis 
were downregulated in the subsequent immune tolerant state (Cheng et al., 2016). 
Furthermore, a metabolically altered profile with predominating fatty acid oxidation 
has been described in endotoxin tolerant blood cells of septic patients (Liu et al., 
2012), implicating metabolic reprogramming in immune tolerance in peripheral cells. 
Further studies will reveal whether the metabolic profile of microglia is changed in 
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similar ways after induction of immune tolerance in the context of neurological 
disease.  
Interestingly, macrophage function can be directly modulated by addition or depletion 
of metabolic factors that impact the balance between glycolysis and mitochondrial 
oxidative phosphorylation (Mills et al., 2016; Mills & O’Neill, 2016). Importantly, a 
causal link between certain metabolites and epigenetic alterations in immune training 
and tolerance has been described in vitro. The Krebs cycle metabolite fumarate 
accumulated in β-glucan trained monocytes and inhibited a family of histone 
demethylases, thereby contributing to the maintenance of open chromatin in trained 
immunity (Arts et al., 2016b). Strikingly, fumarate addition by itself induced 
epigenetic changes resembling immune training in monocytes. In addition, 
nicotinamide adenine dinucleotide (NAD)+-dependent activation of sirtuins, a family 
of histone deacetylases, altered histone acetylation and thereby inhibited gene 
transcription in endotoxin tolerant cells (Liu et al., 2012). These studies highlight the 
close interplay between epigenetic, metabolic, and immune alterations in innate 
immune memory. Our data are in line with this concept and demonstrate changes in 
the epigenetic regulation of gene expression, metabolic state, and immune function of 
microglia after induction of immune training and tolerance. 
Of note, other long-lived cell types in the brain could in theory also possess immune 
memory characteristics and contribute to the described differential modulation of 
brain pathology after training and tolerance. Perivascular and meningeal macrophages 
are, similar to microglia, long-lived cells (Goldmann et al., 2016; Prinz et al., 2017), 
and thus might also be capable of immune memory formation. Astrocytes, which 
contribute to immune reactions in the brain (DeWitt et al., 1998; Liddelow et al., 
2017; Schubert et al., 2000), have – similar to microglia – low turnover rates under 
homeostatic conditions and likely persist for a long time in the brain (Colodner et al., 
2005; Sofroniew & Vinters, 2010). Future studies will reveal whether these cell types 
form immune memory under certain circumstances as described here for microglia. 
This work demonstrates diverse and long-lasting effects of peripheral immune 
stimulation on brain cytokine levels, microglial phagocytosis, and microglial barrier 
function. Microglial barrier function has recently been implicated in AD pathogenesis 
and has been assigned a beneficial role (Condello et al., 2015; Yuan et al., 2016). Our 
study corroborates the described neuroprotective role of the microglial barrier in 
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compacting amyloid plaques, thereby shielding surrounding cells from toxic Aβ 
species. Previous studies showed that the amount of microglial immunoreactivity 
differed between plaque structures (Condello et al., 2015). Whether alterations in 
microglial barrier are cause or consequence of differing plaque structures remains to 
be determined. While we show long-term alterations in microglial function following 
systemic inflammation, no alterations in Aβ processing or onset of Aβ deposition 
were evident, thereby implying alterations in microglial function as the cause of 
changes to amyloid plaque structure. Of note, structurally altered plaques might 
subsequently alter microglial function, rendering it difficult to determine microglial 
phenotype as purely cause or consequence of differences in amyloid plaque structure.  
Our study demonstrates that the long-term effects of training and tolerance persisted 
even at advanced stages of neuropathology, since alterations in amyloid plaque 
structure occurred through different microglia-mediated mechanisms (i.e. reduced 
number of plaque-associated microglia or an altered microglial phenotype). However, 
while training was detrimental and tolerance beneficial in early stages of cerebral β-
amyloidosis, both programs showed detrimental effects on amyloid-associated 
neurotoxicity at a later stage, Such stage-dependent effects of inflammation might 
contribute to the many controversial descriptions of either pro- or anti-inflammatory 
modulation of the immune system as beneficial for pathology in mouse models with 
cerebral β-amyloidosis (Chakrabarty et al., 2015; Heneka et al., 2013; Jay et al., 
2017; Masashi Kitazawa et al., 2011; Shi et al., 2011; Vom Berg et al., 2012).   
Whether microglial immune memory exists in humans and contributes to neurological 
disease remains to be determined. The enhancer and transcriptional landscape of 
human microglia have recently been assessed and showed similarities but also 
differences in several hundred genes, especially genes induced with aging, between 
human and mouse microglia (Galatro et al., 2017; Gosselin et al., 2017). Importantly, 
genetic and epigenetic studies have clearly implicated immunity as a central 
component of AD pathogenesis (Gagliano et al., 2016; Gjoneska et al., 2015; 
Guerreiro et al., 2013; Hollingworth et al., 2011; Huang et al., 2017; Lambert et al., 
2013; Naj et al., 2011; Sims et al., 2017; Zhang et al., 2013). If our study were 
transferable to humans, it would suggest that peripheral infections or any 
inflammatory event in the body might lead to long-lasting alterations in a diverse 
array of microglial functions, which in turn could influence disease onset and 
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pathology progression. Indeed, epidemiological studies suggest that inflammatory 
burden correlates positively with AD (Bu et al., 2014), and conversely long-term use 
of NSAIDs lowers AD risk (Hoozemans et al., 2011). Interestingly, a recent study 
linked increased systemic inflammatory markers in midlife to episodic memory loss 
and reduced brain volume, especially in AD associated regions, more than 20 years 
later (Walker et al., 2017), in line with the idea that systemic inflammation might 
influence much later occurring neurodegenerative processes through long-term 
alterations in microglial functions.  
Our work demonstrates effects of microglial immune memory on pathology in stroke 
and cerebral β-amyloidosis, indicating that modulation of neuropathology is not 
specific to one disease context. Therefore, microglial immune memory could be an 
essential modifier of disease pathogenesis in many other circumstances. Some 
evidence suggests that long-term immune memory also occurs in tissue macrophages 
in other organs, e.g. in lung alveolar macrophages (Chen et al., 2014). Thus, innate 
immune memory of tissue macrophages might be a global mechanism for regulating 
immune activity with yet unresolved consequences for disease. Of note, molecules 
known to induce immune training in macrophages have clinically been used in cancer 
treatment (Kawai et al., 2013; Liu et al., 2015), indicating that innate immune 
memory can aid in fighting diseases with inflammatory components. This work 
demonstrates epigenetically encoded innate immune memory of peripheral 
inflammation in long-lived microglia and highlights its role as an essential modifier of 
neurological diseases. In the future, innate immune memory might emerge as a 
previously unappreciated modifier of many other inflammatory diseases, and applying 
this concept clinically might aid conventional disease therapies.  
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Abstract 
‘Innate immune memory’ is a vital mechanism of myeloid cell plasticity that occurs in 
response to environmental stimuli and alters subsequent immune responses. Two 
types of immunological imprinting can be distinguished, training and tolerance, 
which are epigenetically mediated and enhance or suppress subsequent inflammation, 
respectively. Whether immune memory occurs in tissue-resident macrophages in vivo 
and how it may affect pathology remains largely unknown. Here we demonstrate that 
peripherally applied inflammatory stimuli induce acute immune training and tolerance 
in the brain and lead to differential epigenetic reprogramming of brain-resident 
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macrophages, microglia, that persists for at least six months. Strikingly, in a mouse 
model of Alzheimer’s pathology, immune training exacerbates cerebral β-amyloidosis 
while tolerance alleviates it; similarly, peripheral immune stimulation modifies 
pathological features after stroke. Our results identify immune memory in the brain as 
an important modifier of neuropathology.  
 
Main text 
Contrary to the long-held assumption that immunological memory exists only in cells 
of the adaptive immune system, recent evidence indicates that myeloid cells also 
display memory effects1,2. For example, certain immune stimuli ‘train’ blood 
monocytes to generate enhanced immune responses to subsequent immune insults3,4. 
In contrast, other stimuli induce immune tolerance, i.e. suppression of inflammatory 
responses to subsequent stimuli3,5. Innate immune memory lasts for several days in 
vitro and for up to three months in circulating monocytes in vivo and is mediated by 
epigenetic reprogramming in cultured cells, with chromatin changes also apparent in 
vivo3,6,7. However, whether immune memory occurs in long-lived tissue-resident 
macrophages and whether it alters tissue-specific pathology remains unknown.  
Microglia, the brain-resident macrophages, were recently shown to be very long-lived 
cells8,9. This makes them particularly interesting for studying immune memory, as 
virtually permanent modification of their molecular profile appears possible. As 
microglia are also known to significantly affect many neurological diseases10-12, we 
investigated whether immune memory occurs in microglia in vivo and how it affects 
neuropathology.  
 
Acute immune memory in the brain 
It is well-established that inflammation in the periphery can prompt immune 
responses in the brain13. To evaluate whether immune memory is inducible in the 
brain by peripheral stimulation, mice received daily intraperitoneal injections of low-
dose lipopolysaccharides (LPS) on four consecutive days, leading to mild sickness 
behaviour and temporary weight loss (Fig.1a and Extended Data Fig.1a). Three hours 
after application, the first LPS injection (1xLPS) led to a pronounced increase of 
blood cytokine levels, but only modest increases in brain cytokines. Upon the second 
injection (2xLPS), the blood levels of the pro-inflammatory cytokines IL-1β, TNF-α, 
IL-6, IL-12 and IFN-γ were diminished compared to 1xLPS while IL-10 release 
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occurred at similar levels, indicating peripheral immune tolerance. In sharp contrast, 
brain cytokines were dramatically increased with 2xLPS injections, indicating a brain-
specific training effect induced by the first LPS stimulus (Figs.1b/c and Extended 
Data Fig.2). Accordingly, a conspicuous morphological change in microglia occurred 
after 2xLPS, while activated (GFAP+) astrocytes only increased after 3xLPS 
(Extended Data Figs.1b-d). Importantly, 4xLPS virtually abolished TNF-α, IL-1β and 
IL-6 release in the brain while IL-10 remained elevated, indicating immune tolerance.  
Next, we examined the contribution of microglia to immune memory in the brain 
using inducible CX3CR1-CreER (Cre) mice crossed with mouse lines carrying loxP-
flanked genes, where tamoxifen-induced Cre expression results in persistent 
recombination in long-lived microglia but not in short-lived myeloid cells, including 
blood monocytes14. We induced microglial knockout of either ‘transforming growth 
factor-β-activated kinase 1’ (Tak1), which results in inhibition of NF-kB, JNK and 
ERK1/2 pathways14, or histone deacetylases-1 and -2 (Hdac1/2), two major regulators 
of epigenetic reprogramming and macrophage inflammatory responses15,16. As 
expected, tamoxifen-induced knockout of either Tak1 or Hdac1/2 did not alter the 
peripheral inflammatory response. Furthermore, brain cytokine levels were 
indistinguishable after 1xLPS, but the training effect following 2xLPS injections was 
virtually abolished in Cre+ animals. Notably, the cytokines showing the most 
pronounced training and tolerance effects (IL-1β, TNF-α, IL-6) were also most 
affected by microglial gene knockout (Figs.1b/c and Extended Data Fig.2), indicating 
that immune memory in the brain is predominantly microglia-mediated. Moreover, 
after 1xLPS, Cre+ and Cre– mice showed indistinguishable weight loss (Extended 
Data Fig.1a) and sickness behaviour (not shown); however, in animals with microglial 
Tak1 knockout, sickness behaviour after 2xLPS was noticeably alleviated 
(Supplementary Movie 1).  
After intraperitoneal injections, LPS was found in the blood but not in the brain, 
indicating that neither significant entry of LPS into the brain nor opening of the 
blood-brain barrier occurred, corresponding with previous reports17. The latter was 
confirmed by the absence of blood iron in the brain parenchyma. Also, using 'type 2 
CC chemokine receptor’ (CCR2) reporter mice18, no extravasation of circulating 
monocytes was found (Extended Data Figs.1e-g), confirming that immune memory 
was mediated by brain-resident macrophages alone. 
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Immune memory shapes neuropathology 
Next, we analysed whether the training- and tolerance-inducing stimuli 1xLPS and 
4xLPS, respectively, could lead to long-term alterations of brain immune responses 
and thereby modify disease pathogenesis. APP23 mice are a model of Alzheimer’s 
disease (AD) pathology, where plaques of insoluble amyloid-β develop from 6 
months of age. Amyloid plaques lead to activation of microglia19, thereby providing a 
stimulus that should reveal microglial immune memory. We injected 3-month-old 
APP23 mice with 1x/4xLPS, then analysed pathology 6 months later (Fig.2a). 
Strikingly, 1xLPS significantly increased while 4xLPS significantly decreased both 
plaque load and total amyloid-β levels compared to control animals (Fig.2b), with 
plaque-associated neuritic damage correlating directly with plaque size in all 
treatment groups (Extended Data Figs.3a-c). Also, the protein levels of amyloid-β 
precursor protein (APP) and its cleavage products were indistinguishable amongst 
groups, indicating equivalent amyloid-β generation (Extended Data Fig.3d). 
Furthermore, neither the total number of microglia nor the number of microglia 
clustering around plaques was altered by LPS treatments (Fig.2c), while the number 
of activated (GFAP+) astrocytes decreased slightly both with 1x and 4xLPS treatment 
(Extended Data Fig.3e). However, the brain levels of IL-1β, IL-6 and IL-12 were 
reduced in 4xLPS-treated APP animals, while in 1xLPS-treated APP mice IL-10 was 
reduced. In contrast, brain cytokine levels were not altered in wildtype littermate 
controls and baseline blood cytokine levels were unchanged in wildtype and APP 
animals. Furthermore, an additional LPS injection at 9 months of age caused 
indistinguishable peripheral cytokine responses (Fig.2d and Extended Data Figs.4a-c). 
Thus, peripheral immune stimuli cause long-term alterations in the brain immune 
response and differentially affect AD pathology. 
To test for immune memory effects in a second disease model, we injected wildtype 
animals with 1x/4xLPS and induced focal brain ischemia one month later. One day 
post-ischemia, neuronal damage and microglial numbers were indistinguishable 
amongst treatment groups (Fig.3a), indicating that the initial ischemic insult was 
unaffected by 1x/4xLPS. However, the acute inflammatory response, which is driven 
by brain-resident cells early after ischemia12, differed, showing increased levels of IL-
1β in 1xLPS- and decreased levels in 4xLPS-treated animals. In contrast, the release 
of IL-10 was significantly suppressed by 1xLPS only (Fig.3b), reminiscent of results 
in APP animals (Fig.2d). Other brain cytokines and blood cytokine levels were 
 77 
indistinguishable amongst groups (Extended Data Fig.5). Importantly, seven days 
after brain ischemia, the volume of neuronal damage and microglial activation was 
strongly reduced by 4xLPS but unaffected by 1xLPS (Figs.3c/d). These results 
confirm long-term modulation of brain immune responses and suggest persistent 
modification of stroke pathology following a tolerizing but not a training stimulus, 
possibly due to the severity of the insult preventing its further exacerbation through 
amplification of the immune response.  
 
Microglial molecular profiles 
In vitro, immune memory in macrophages results from epigenetically-mediated 
alterations in the enhancer repertoire, leading to transcriptional changes3,20,21. Since 
our data indicated that acute immune memory in the brain is mediated predominantly 
by microglia, we isolated microglia by cell sorting (Extended Data Fig.6) from 9-
month-old animals stimulated with 1x/4xLPS at 3 months of age and performed 
chromatin immunoprecipitation for mono-methylation at lysine 4 of histone 3 
(H3K4me1) and acetylation at lysine 27 of histone 3 (H3K27ac), which define active 
enhancers20,21. Thus, we identified 20,241 putative active enhancers across all 
conditions.  
First, we focussed on H3K4me1 marks, which should mark all enhancers activated in 
response to the first and/or second immune stimulus (as enhancers may lose H3K27ac 
after cessation of inflammation but retain H3K4me1 marks)20,21. Strikingly, 
H3K4me1 levels differed significantly between control and LPS treatment groups 
both in wildtype and APP animals but also between 1x- and 4xLPS-treated mice 
(Extended Data Fig.7b; Supplementary Table1). For example, enhancers with 
increased H3K4me1 levels in microglia from 1xLPS versus 4xLPS wildtype animals 
showed enrichment for the ‘thyroid hormone signalling pathway’, including a putative 
enhancer for hypoxia inducible factor-1α (HIF-1α). Similarly, enhancers with higher 
H3K4me1 levels in 1xLPS versus 4xLPS-treated APP mice were enriched for the 
‘HIF-1 signalling pathway’. On the other hand, 4xLPS-treated APP animals showed 
increased H3K4me1 levels in putative enhancers related to phagocytic function 
(Fig.4a). Importantly, no pathway enrichment was found when comparing H3K4me1 
levels in microglia from APP and wildtype controls (Fig.4a), indicating that 
H3K4me1 levels were altered predominantly in response to LPS stimulation.  
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Next, we analysed enhancer activation by determining differential regulation of 
H3K27ac levels. In line with the requirement of an acute stimulus for H3K27ac 
deposition20, differential enhancer activation was more pronounced in APP animals 
(where amyloid plaques activate microglia) than in wildtype groups (190±18 in APP, 
69±5 in wildtype groups; Extended Data Fig.7e; Supplementary Table2). For 
example, differentially regulated H3K27ac levels in microglia from 1xLPS-treated 
versus control APP animals were enriched for the ‘HIF-1 signalling pathway’, with 
enhancer regions also being enriched for HIF-1α binding motifs (Fig.4b and Extended 
Data Fig.8), in line with changes in H3K4me1 levels (Fig.4a) and the reported key 
role of HIF-1α in trained immunity and macrophage inflammatory responses4,22.  
Active enhancers in microglia from 4xLPS-treated versus control APP animals only 
showed enrichment for the ‘Rap1 signalling pathway’, a pathway implicated in 
phagocytosis of opsonized targets23,24, again matching changes in H3K4me1 levels 
(Figs.4a/b). Strikingly, the comparison of microglia from APP animals that received 
the training- (1xLPS) and tolerance-inducing (4xLPS) stimuli, showed no pathway 
enrichment for active enhancers in 4xLPS-treated animals while enhancers in 1xLPS-
treated animals were enriched for a large number of inflammation-related pathways, 
highlighting the differential effects of the two immune memory states. Finally, the 
comparison of microglia from vehicle-treated wildtype and APP animals 
demonstrated a small number of differentially activated enhancers with enrichment 
for the ‘thyroid hormone signalling pathway’ (including a putative active enhancer for 
Hif1a) as well as the ‘mTOR signalling pathway’ (Fig.4b), indicating that microglia 
are also epigenetically reprogrammed in response to brain pathology alone.  
We next examined microglial mRNA levels under the same conditions to determine 
whether epigenetic alterations were reflected in gene expression levels 
(Supplementary Table3). First, we determined the concordance between 772 
enhancers with significantly increased/decreased H3K27ac levels (Supplementary 
Table2) and the direction of change in the expression of their nearest gene. Indeed, 
there was a significant (albeit modest) concordance between alterations in H3K27ac 
levels and gene expression (median concordance of pairwise comparisons =58%, 
P=0.03). This suggested that gene expression is directly affected by the microglial 
active enhancer repertoire. Accordingly, weighted gene correlation network analysis 
(WGCNA25) revealed striking parallels to epigenetic changes (Figs.5a-c and 
Supplementary Table4). For example, the red module (MEred) contained the Hif1a 
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gene, showed enrichment for the ‘HIF-1 signalling pathway’ and correlated strongly 
with the 1xLPS-treated APP group. Furthermore, gene expression in MEred was 
significantly upregulated in APP versus wildtype control animals and further 
increased by 1xLPS but downregulated by 4xLPS treatment.  
HIF-1α activation in inflammatory-stimulated macrophages can occur downstream of 
mitochondrial hyperpolarization; enhanced HIF-1α signalling in turn promotes 
glycolysis, measurable as lactate release26. Accordingly, the green module (MEgreen), 
which correlated positively with control and 1xLPS-treated APP groups but 
negatively with control and 4xLPS-treated wildtype groups, was found to be enriched 
in genes of the ‘glycolysis’ pathway. Microglial gene expression in MEgreen was 
upregulated in APP versus wildtype control animals and again further increased in 
APP animals by 1xLPS but decreased by 4xLPS treatment. Therefore, we analysed 
mitochondrial membrane potential and lactate release in microglia. Strikingly, 
microglia from 1xLPS-treated APP animals showed strongly increased mitochondrial 
membrane potential, which correlated positively with the release of lactate (Fig.5d), 
functionally corroborating the epigenetic and transcriptional alterations in trained 
microglia. Additionally, immunostaining confirmed higher protein levels of HIF-1α in 
plaque-associated microglia, which were further increased in 1xLPS-treated APP 
animals (Figs.5e/f). Thus, HIF-1α signalling and a metabolic switch to glycolysis are 
activated in response to cerebral β-amyloid deposition, and are enhanced by immune 
training but reduced by immune tolerance in microglia. 
In contrast to MEred/green, MEgrey correlated positively with the control wildtype 
but negatively with control and 1xLPS-treated APP groups. Compared to wildtype 
controls, microglial gene expression in MEgrey was downregulated in APP control 
animals and further decreased by 1xLPS stimulation, but showed unchanged levels in 
4xLPS-treated APP animals (Figs.5a-c). Importantly, MEgrey was enriched for 
phagocytosis-related pathways, including the ‘Rap1 signalling pathway’ (Figs.5a-c), 
again reflecting epigenetic changes (Fig.4). We therefore tested whether phagocytosis 
of Aβ was enhanced in 4xLPS-treated APP animals. Indeed, microglial Aβ content 
was increased ~1.75-fold in 4xLPS-treated compared to APP control animals 
(Fig.5g), providing further functional validation of the microglial enhancer repertoire 
and gene expression profiles.  
Recent data indicate that context-specific microglial phenotypes exist, e.g. ‘disease-
associated microglia’ (DAM27) and the ‘microglial neurodegenerative phenotype’ 
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(MGnD28). Interestingly, the brown module (MEbrown), which was significantly 
upregulated by both LPS treatments in wildtype as well as in all APP groups, 
contained a number of homeostatic microglial genes (e.g. Hexb, Cx3cr1, Csf1r) but 
also all of the ‘stage 1 DAM’ core-genes except Apoe, as well as 4 of 12 ‘stage 2’ 
core-genes27 (Fig.5c). Of note, the gene encoding ApoE, which may be crucial for 
promoting a detrimental microglial phenotype28,29 was found in the same module as 
Hif1a (MEred). MEred also contained other genes genetically linked to AD risk, 
namely Cd33 and Inpp5d30, suggesting that HIF-1α may also be a detrimental 
modulator of AD pathology.  
 
The epigenetic landscape of microglia has only been described under homeostatic 
conditions31-33. Our data now demonstrate epigenetic modifications in microglia in 
response to peripheral immune stimulation but also as a result of cerebral β-
amyloidosis, including activation of the HIF-1α and mTOR pathways, and leading to 
transcriptional and functional alterations. While the global epigenetic and 
transcriptional changes were relatively modest, they were likely driven by a small 
number of microglia that received the required secondary immune stimulation, as 
evidenced for example by increased levels of HIF-1α in plaque-associated microglia 
(Fig.5). mTOR activation is a well-known event in early AD34 and was recently 
shown in microglia, where it activated HIF-1α and glycolysis to sustain microglial 
energy demand in AD models35. Our data now indicate that mTOR activation may be 
mediated by epigenetic microglial reprogramming in response to cerebral β-
amyloidosis and that HIF-1α signalling downstream of mTOR could be a detrimental 
event, because augmentation or suppression of HIF-1α signalling occurred 
concomitantly with aggravated or alleviated Aβ deposition, respectively.  
We here provide evidence of both immune training and tolerance in microglia and 
demonstrate their impact on neuropathology for the first time. While we cannot 
completely exclude that other cell-types contribute to immune memory and 
modulation of pathology in the brain, microglial-specific gene knockout of Tak1 or 
Hdac1/2 virtually abolished immune training (Fig.1), indicating that microglia are 
likely the major effectors of immune memory. Importantly, in our experiments, 
immune memory effects mostly became apparent following a secondary inflammatory 
stimulus, corroborating the concept of innate immune memory1,3. However, while in 
the periphery training may be beneficial due to enhanced pathogen elimination7,36,37, 
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and tolerance may be detrimental due to higher rates of infection resulting from 
immune suppression5, we found that training promotes while tolerance alleviates 
neuropathology. This is consistent with the beneficial effects of preventing microglial 
pro-inflammatory responses in models of AD pathology and stroke12,38 and the 
worsening of cerebral β-amyloidosis in response to pro-inflammatory peripheral 
stimuli in animal models39. Similarly, immune training has recently been described in 
epithelial stem cells, where it promotes wound healing but may also underlie 
autoimmune disorders40. Thus, immune memory in the brain could conceivably affect 
the severity of any neurological disease that presents with an inflammatory 
component, but this will need to be studied for each individual condition.  
Our data provide proof-of-principle for innate immune memory in microglia, and 
while our different LPS injection paradigms may not necessarily model physiological 
stimuli, we found that individual cytokines applied peripherally may also elicit 
immune memory effects in the brain (Extended Data Fig.9). These results suggest that 
a wide variety of immune challenges may induce microglial immune memory and 
provide a possible mechanism for LPS-induced immune memory in the brain. It will 
be crucial to determine which other stimuli may lead to long-term modulation of 
microglial responses and thereby contribute to the severity of many neurological 
diseases. 
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Figure 1: Peripheral immune stimulation evokes immune memory in microglia. 
a, Experimental approach. b, White bars: Peripheral cytokine levels in wildtype/APP23 animals 
following lipopolysaccharide (LPS) injections. Note that tolerance is induced with repeated 
injections. c, Brain cytokine levels: 2xLPS amplifies IL-1β/TNF-α release, demonstrating immune 
training; tolerance occurs with 3x/4xLPS. Cytokines return to baseline within 24h 
(1xLPS,1xPBS/4xLPS+1day). Grey bars: Microglia-specific knockout of Tak1 or Hdac1/2 
selectively prevents immune training in the brain. In (b/c) n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 from 
left to right. */**/***P  <0.05/  0.01/0.001 for independent-samples median test with correction for 
multiple comparisons. Data are means±s.e.m. 
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Figure 2: Cerebral β-amyloidosis is altered after peripheral immune stimulation.  
a, Experimental design. b, Analysis of cortical amyloid-β plaque load (n=22,10,10 animals) and 
protein levels (n=14,10,10 animals). c, Analysis of total cortical and plaque-associated microglia 
(n=7,7,7,14,10,10 animals) and d, cytokine levels of IL-10 and IL-1β in wildtype and APP23 mice 
(n=8,8,7 and n=14,10,10 animals). Scale bar: 50 µm. */**/***P  <0.05/0.01/  0.001 for one-way (b) 
and two-way ANOVA (c/d) with Tukey correction. Data are means  ±  s.e.m. 
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Figure 3: Stroke pathology is altered after peripheral immune stimulation. 
Pathological features of brain ischemia induced one month after intraperitoneal injection with 1x or 
4xLPS. a, Neuronal damage (cresylviolet, n=6,6,7,6 animals), microglial numbers (Iba1-positive, 
n=6,6,6 animals) and b, cytokine profiles one day post-ischemia (n=5,7,5,5 animals). c, Overview 
of microglial activation in the infarct and d, quantification of neuronal damage and microglial 
activation seven days post-ischemia (n=3,13,8,9 animals). Scale bar: 500 µm. */**/*** 
P  <0.05/0.01/  0.001 for one-way ANOVA with Tukey correction. Data are means  ±  s.e.m. 
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Figure 4: The microglial enhancer repertoire 6 months after immune stimulation.  
Pathway enrichment of enhancers (with Benjamini-Hochberg correction) with differentially 
regulated H3K4me1 (a) and H3K27ac (b) levels (based on nearest gene; cumulative Poisson P-
value <0.0001). n=2 replicates (8-10 animals/replicate).  
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Figure 5: Microglial gene expression and function 6 months after immune stimulation. 
a, Weighted gene correlation network analysis (top: correlation coefficient; bottom: P-value; 
n=9,9,6,6,5,4 animals). b, Selected KEGG pathways enriched in modules. c, Heatmaps of genes 
within modules, z-scores (boxplot whiskers: 5-95th percentile; n=1601,990,949,3543 genes in 
modules) and selected genes. d, Microglial mitochondrial membrane potential (left/middle; 
n=9,6,6,8,3,4 animals) and Pearson’s correlation with lactate release (right; n=11,10,10 animals). e, 
Staining for top: HIF-1a, microglia (CD11b) and amyloid plaques (Methoxy-X04) and bottom: HIF-
1a and microglial nuclei (Pu.1; single confocal plane) in brain sections from 9-month-old animals. 
Scale bars: 20/5 µm (top/bottom).  f, Total cellular (n=7,7,7 animals) and nuclear (n=8,8,7 animals) 
HIF-1a staining intensity. g, Microglial Aβ content (n=5,11,10,10 animals). */**/*** 
P<0.05/0.01/0.001 for one-way ANOVA with Tukey correction. Data are means±  s.e.m.  
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Materials and Methods 
 
Animals 
For all experiments, 3 month-old hemizygous APP23 transgenic (C57BL/6J-
Tg(Thy1-APPK670N;M671L)23), APP23 transgene-negative littermates or C57BL/6J 
(wildtype) mice (Jackson Laboratory) were used.  
For experiments analysing immune responses after acute LPS and cytokine 
stimulation (see below), both male and female mice were used. For microglia-specific 
gene knockouts, CX3CR1-CreER animals were crossed with Tak1 fl/fl animals and 
Cre recombinase expression was induced by subcutaneous tamoxifen injections as 
previously described14. Similarly, microglial-specific knockout of Hdac1/2 was 
achieved after crossing CX3CR1-CreER animals with a Hdac1/2 fl/fl line15. Both 
Tak1 fl/fl and Hdac1/2 fl/fl were injected at 2-3 months of age and were incubated for 
four weeks without further treatment. Tamoxifen-injected CX3CR1-Cre negative 
littermates were used as controls (because responses in CX3CR1-Cre negative 
animals were indistinguishable in Hdac1/2 fl/fl and Tak1 fl/fl lines, pooled data are 
shown in Fig. 1).  
As there is a significant gender effect on the pathology of both brain ischemia and 
cerebral β-amyloidosis,41,42 only female mice were used for the analyses of brain 
pathology. APP23 mice express a transgene consisting of human amyloid-β precursor 
protein (APP) with the KM670/671NL mutation under the Thy-1 promoter, and have 
been backcrossed with C57BL/6J mice for >20 generations. Female mice develop 
cerebral β-amyloid lesions in the neocortex around 6 months of age19.  
Animals were maintained under specific pathogen-free conditions. All experiments 
were performed in accordance with the veterinary office regulations of Baden-
Württemberg (Germany) and were approved by the Ethical Commission for animal 
experimentation of Tübingen and Freiburg, Germany. 
 
Peripheral immune stimulation 
3-month-old mice were randomly assigned to treatment groups and were injected 
intraperitoneally (i.p.) with bacterial lipopolysaccharides (LPS from Salmonella 
enterica serotype typhimurium, Sigma) at a daily dose of 500 µg/kg bodyweight. 
Animals received either four LPS injections on four consecutive days (4xLPS), a 
single LPS injection followed by three vehicle injections on the following three days 
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(1xLPS) or four vehicle injections (PBS). Acute stimulation showed indistinguishable 
cytokine responses in wildtype and APP23 transgenic animals; Figure 1 shows the 
pooled data from both genotypes (see Extended Data Fig. 2 for data separated by 
genotype). Furthermore, as cytokine responses were indistinguishable in animals 
treated with 1/2/3/4xPBS, pooled data from all time points are shown. 
For peripheral cytokine treatments, recombinant murine cytokines (TNF-α, IL-10; 
PeproTech) were aliquoted as by the manufacturer’s instructions and stored at -80°C 
until use. To determine whether a long-term change in the brain’s immune response 
(training or tolerance) occurred after peripheral cytokine injection, mice were treated 
on four consecutive days with 0.1 µg/g bodyweight IL-10 or once with 0.1/0.2 µg/g 
bodyweight TNF- α. Control mice received four vehicle injections (PBS). Four weeks 
later, cytokine- and control-treated mice received LPS (1 µg/g bodyweight) or PBS, 
and were prepared 3 hours after the injection. 
At the specified time-points, animals were deeply anaesthetised using 
sedaxylan/ketamine (64 mg/kg//472 mg/kg), blood was collected from the right 
ventricle of the heart and animals were transcardially perfused with ice-cold PBS 
through the left ventricle. The brain was removed and sagitally separated into the two 
hemispheres, which were either fixed in 4% paraformaldehyde (PFA) or fresh-frozen 
on dry ice. Fresh-frozen hemispheres where homogenised using a Precellys® lysing 
kit and machine at 10 or 20% (w/v) in homogenisation buffer (50 mM Tris pH 8, 150 
mM NaCl, 5 mM EDTA) containing phosphatase and protease inhibitors (Pierce). 
Fixed hemispheres were kept in 4% PFA for 24h, followed by cryoprotection in 30% 
sucrose in PBS, subsequently frozen in 2-methylbutane and coronally sectioned at 25 
µm using a freezing-sliding microtome (Leica).  
 
Focal brain ischemia 
For the induction of a focal cortical stroke, we modified existing models of 
endothelin-1 (ET-1)-induced brain ischemia43 to avoid traumatic injury to the brain. 
Under anaesthesia and analgesia (Fentanyl, Midazolam, Medetomidin: 0.05//5//0.5 
mg/kg bodyweight), 3-month-old animals were fixed in a stereotactic frame and a 
circular piece of skull was removed (5 mm diameter, centred on Bregma; as described 
in44). The dura mater was carefully removed with the help of a microhook (Fine 
Science Tools) and 5 µl of ET-1 (Bachem; 64 µM) in Hanks Buffered Salt Solution 
(Invitrogen) or vehicle solution was topically applied to the cortex and incubated for 
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10 min. The craniotomy was then covered with a 5 mm glass coverslip, which was 
fixed in place with dental cement (Hybond), the skin was sutured, then the mice 
received antidote (Flumazenil, Atipamezol: 0.5//2.5mg/kg bodyweight) and were 
health-monitored. Control mice underwent the same surgical procedure with 
application of vehicle solution to the cortex. After 4 weeks, animals were deeply 
anesthetized and prepared as described above. 
 
Western Blotting analysis 
For Western Blotting, total brain homogenates were sonicated 3x5 seconds 
(LabSonic, B. Braun Biotech), protein levels of the brain homogenates were 
quantified with a microplate bicinchoninic acid (BCA) assay (Pierce) and adjusted 
accordingly. Samples were then analysed on NuPage Bis-Tris gels (Invitrogen) using 
standard procedures. Proteins were transferred to nitrocellulose membranes, blocking 
was performed with 5% milk in PBS containing 0.05% Tween (PBST) for 1h and 
blots were incubated with mouse anti-Aβ (6E10; 1:1000, Covance) in PBST overnight 
at 4°C. Membranes were then probed with the secondary HRP-labelled antibodies 
(1:20,000, Jackson ImmunoLaboratories). Protein bands were detected using 
chemiluminescent peroxidase substrate (ECL prime, GE Healthcare). Densitometric 
values of the protein band intensities were analysed with the software package Aida 
v.4.27 and normalised to GAPDH intensities. 
 
Immunostaining 
Immunohistochemical staining was performed on free-floating sections using either 
Vectastain Elite ABC kits (Vector laboratories) or fluorescent secondary antibodies 
(Jackson Immunolaboratories). Unless otherwise noted, brain sections were blocked 
for 1h with 5% normal serum of the secondary antibody species, followed by primary 
antibody incubation overnight at 4°C. Primary antibodies used were: rabbit anti-Pu.1 
(1:1000, Cell Signalling), rabbit anti-Iba1 (1:1,000; Wako; catalogue no. 019-19741), 
rabbit anti-GFAP (1:500, Biozol; catalogue no. Z0334), rabbit anti-Aβ (CN3; 
1:2,00045), mouse anti-HIF-1α (1:500; Novus Biologicals, catalogue no. NB100-105, 
clone H1alpha67), rat anti-CD11b (1:2000; Millipore, catalogue no. MAB1387Z), 
rabbit anti-APP (antibody 5313 to the ectodomain of APP, 1:750; kind gift of Prof. 
Christian Haas, Munich). Sections were then washed and incubated with secondary 
antibodies. Cresylviolet and Congo Red staining was conducted according to standard 
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procedures. Fluorescent plaque staining was achieved using Methoxy-X04 (4% vol of 
10 mg/ml methoxy-X04 in DMSO, and 7.7% vol CremophorEL in 88.3% vol PBS) 
for 20 min, RT.  
Images were acquired on an Axioplan 2 microscope with Axioplan MRm and 
AxioVision 4.7 software (Carl Zeiss). Fluorescent images were acquired using a LSM 
510 META (Axiovert 200M) confocal microscope with an oil immersion 63X/1.4NA 
objective and LSM software 4.2 (Carl Zeiss), using sequential excitation of 
fluorophores. Maximum-intensity projections were generated using IMARIS 8.3.1 
software (Bitmap).  
For quantitative comparisons, sections from all groups were stained in parallel and 
analysed with the same microscope settings by an observer blinded to the treatment 
groups. To quantify the intensity of total microglial HIF-1α staining, high-resolution 
bright field images were acquired using fixed camera exposure time and lamp 
intensity and subsequently analysed with Fiji software. Colour channels were split and 
a fixed intensity threshold was applied to the red channel. On each image, the 
thresholded area over the total image area was calculated. Area fractions were 
measured on images of at least 9 plaques and 15 plaque-free regions per animal. To 
exclude an influence of plaque-size on microglial HIF-1α levels, plaques of similar 
size were selected for analysis of HIF-1α levels in the different treatment groups 
(average plaque size: PBS i.p.: 1.73±0.15, 1xLPS i.p.: 1.84±0.19, 4xLPS i.p. 
2.27±0.39% Congo red area fraction).  
For nuclear HIF-1α staining, a modified staining protocol was used. Briefly, sections 
were blocked with mouse Ig blocking reagent (Vector laboratories) for 1h, RT, 
followed by blocking with normal donkey serum for 1h, RT. Sections were then 
incubated overnight with mouse anti-HIF1α (clone mgc3, 1:50; Thermo Fisher 
Scientific, catalogue no. MA1-516) and rabbit anti-Pu.1 (1:250; New England 
Biolabs, catalogue no. 2258S. Clone 9G7), 4°C. To quantify the intensity of nuclear 
HIF-1α staining, z-stacks from 3 plaques and plaque-free regions per animal were 
acquired with the same microscope settings and subsequently analysed with IMARIS 
8.3.1 software. Using the surfaces tool, a mask based on microglial nuclei was created 
using staining for Pu.1. A filter for area was applied to exclude background staining. 
The created surface was used to mask the HIF-1α channel. The mean masked HIF-1α 
intensity was then determined. 
 95 
To quantify neuronal dystrophy, fluorescent images from 5-10 plaques per animal 
were acquired with the same microscope settings and subsequently analysed with Fiji 
software. Maximum intensity projections were generated to choose the region of 
interest consisting of APP-staining and the plaque. Fluorescence channels were split 
and intensity thresholds were applied to each channel. For every plaque, the 
thresholded area within the region of interest was calculated as a measure of plaque 
size and dystrophic area. 
 
Stereological and morphological quantification 
Stereological quantification was performed by a blinded observer on random sets of 
every 12th systematically sampled 25 µm thick sections throughout the neocortex. 
Analysis was conducted using the Stereologer software (Stereo Investigator 6; MBF 
Bioscience) and a motorized x-y-z stage coupled to a video microscopy system 
(Optronics). For quantification of total Pu.1- and GFAP-positive cells, the optical 
fractionator technique was used with three-dimensional dissectors as previously 
described46. For the quantification of plaque-associated cells, plaques were identified 
based on Congo Red staining and cells in their immediate vicinity were counted. 
Plaque load was determined by analysing the cortical area covered by Congo Red 
and/or anti-Aβ staining using the area fraction fractionator technique46. The volume of 
neuronal damage and microglial activation after brain ischemia was determined using 
the Cavalieri estimator technique.  
For analysing microglial morphology, three images from three non-consecutive brain 
sections per animal were acquired from Iba-1 immunostained sections using identical 
camera acquisition settings, at 20X/0.5NA magnification. In order to perform the 
filament tracing in IMARIS (v.8.3.1), images were pre-processed in Fiji to optimise 
their contrast for reconstruction. The image background was subtracted using the in-
built Fiji plugin to obtain an evenly distributed intensity and enhance contrast to the 
cells; subsequently the images were sharpened and their intensity was adjusted to the 
respective minimum and maximum histogram values. Filaments were then traced in 
IMARIS using the in-built Autopath algorithm. Reconstruction parameters were kept 
constant among all images; each cell was reconstructed as a 'filament' element in 
IMARIS, associated with a total length and volume. 
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ELISA 
For quantification of Aβ by ELISA (Meso Scale Discovery) in brain homogenates or 
by SIMOA (Single Molecule Array, Quanterix) in isolated microglial cells, samples 
were pre-treated with formic acid (Sigma-Aldrich, final concentration: 70% vol/vol), 
sonicated for 35 seconds on ice, and centrifuged at 25,000g for 1 hour at 4°C. 
Neutralization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05% NaN3 (wt/vol)) was 
then added at a 1:20 ratio. Aβ was measured by an observer blinded to the treatment 
groups using human (6E10) Aβ triplex assay (Meso Scale Discovery, MSD) in brain 
homogenates or Simoa Human Abeta 42 2.0 Kit (Quanterix) in isolated microglia 
according to the manufacturer’s instructions.  
Soluble APPβ containing the Swedish mutations (as present in the APP23 transgene) 
was measured using the sw soluble APPβkit (Mesoscale Discovery) following the 
manufacturer’s instructions after extraction with 1% Triton-X 100 and 
ultracentrifugation for 1h, 135,000g, 4 °C.  
For cytokine measurements, brain homogenates were centrifuged at 25,000g for 30 
minutes at 4°C. Supernatants were analysed using the mouse pro-inflammatory panel 
1 V-plex plate (Mesoscale Discovery) according to the manufacturer’s instructions. 
To determine blood cytokines, serum was obtained by coagulation of whole blood in 
Vacuettes (Greiner Bio-One) for 10 min, RT, and centrifugation for 10 min, 2,000g. 
Serum samples were diluted 1:2 before measurements. The investigator was blinded 
to the treatment groups.  
Measurements were performed on a Mesoscale Sector Imager 6000 or a Simoa HD-1 
Analyzer. For analyses of brain homogenates, protein levels were normalised against 
total protein amount as measured by BCA protein assay (Pierce).  
To determine levels of LPS in blood and brain homogenates, the Limulus Amebocyte 
Lysate assay was used according to the manufacturer’s instructions (Pierce LAL 
Chromogenic Endotoxin Quantitation Kit). Standards were prepared either in serum 
or brain homogenate from non-injected control animals. Serum samples were diluted 
1:100 and brain homogenates 1:5 to eliminate matrix effects. 
 
Isolation of microglia and fluorescence-activated cell sorting (FACS) analysis 
Fluorescence-activated cell sorting of microglia was performed based on CD11bhigh 
and CD45low as previously described9 (see also Extended Data Fig.6). 
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Assessment of microglial mitochondrial membrane potential and lactate release 
To assess the microglial mitochondrial membrane potential, 10k microglia were 
sorted into 70 µl PBS. Cells were incubated at 37°C with 3,3'-
Dihexyloxacarbocyanine Iodide, DiOC6(3) (Thermo Fisher Scientific) at a final 
concentration of 0.2 nM for 20 minutes. At this concentration, mitochondrial dye 
accumulation is largely dependent on the mitochondrial membrane potential, with 
only minor contributions of the plasma membrane potential47. After incubation, the 
cell suspension was diluted with ice-cold PBS and DiOC6(3) fluorescence was 
immediately acquired with a Sony SH800 instrument.  
For the assessment of microglial lactate release, 50k microglia from the same animals 
as used for DiOC6(3) staining were plated in 96-well plates with 125 µl of 
macrophage serum-free medium (Thermo Fisher Scientific) and incubated for 24h at 
37°C, 5% CO2. Lactate concentration in the media was determined using a Lactate 
Assay Kit (BioVision) following the manufacturer’s instructions and was correlated to 
DiOC6(3) fluorescence values from cells of the same animal using IBM SPSS 
Statistics 22 software. 
 
RNA-sequencing 
For RNA sequencing, 10k microglia were directly sorted into RNAse-free PCR strips 
containing 30 µl of H2O with 0.2% Triton-X and 0.8 U/µl RNAse inhibitor (Clontech) 
and samples were immediately frozen on dry ice. RNA was isolated using NucleoSpin 
RNA XS kit (Macherey-Nagel) according to the manufacturer’s instructions. 3 ng 
total RNA was used as input material for cDNA synthesis. cDNA synthesis and 
enrichment was performed following the Smart-seq2 v4 protocol as described by the 
manufacturer (Clontech). Sequencing Libraries were prepared with 1 ng of cDNA 
using the Nextera XT library preparation kit (Illumina) as described48. Multiplexing of 
samples was achieved using three different index-primers in each lane. For 
sequencing, samples from each group (APP and WILDTYPE) were pooled to rule out 
amplification and sequencing biases. Libraries were quality-controlled and quantified 
using a Qubit 2.0 Fluorometer (Life Technologies) and Agilent 2100 Bioanalyzer 
(Agilent Technologies). Final library concentration of 2 nM was used for sequencing. 
Sequencing was performed using a 50 bp single read setup on the Illumina HiSeq 
2000 platform. Base calling from raw images and file conversion to fastq files were 
achieved by Illumina standard pipeline scripts (bcl2fastq v.2.18.0).  
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Quality control was then performed using FASTQC (v.2.18.0) program 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), eliminating one sample 
which had less than 20 million reads. Reads were trimmed off for sequencing adaptor 
and were mapped to mouse reference transcriptome (mm10) using STAR aligner 
2.5.2b with non-default parameters. Unique read counts were obtained for each 
sample using HOMER v.4.8 software (http://homer.salk.edu/homer/) and 
‘maketagdirectory -tbp 1’ command, followed by ‘analyzeRepeats.pl rna mm10 -
count exons -noadj -condenseGenes’. Raw read counts were imported into R (v.3.2) 
and normalized using the Bioconductor (v.3.2) DESeq2 package (v.1.10.1) using 
default parameter. After normalization, all transcripts having a maximum overall 
group mean lower than 10 were removed. Unwanted or hidden sources of variation, 
such as batch and preparation date, were removed using the sva package49. The 
normalized rlog transformed expression values were adjusted according to the 
surrogate variables identified by sva using the function removeBatchEffect from the 
limma package50. To determine gene clusters associated with wildtype or APP23 
animals following i.p. injections of 1x or 4xLPS at 3 months of age, we then used the 
13,627 present genes and applied the R implementation of the Weighted Gene 
Correlation Network Analysis (WGCNA). We then performed WGCNA clustering 
using the ‘1-TOMsimilarityFromExpr’ function with the network type "signed 
hybrid", a power parameter of 7 (as established by scale free topology network 
criteria), and a minimum module size of 50 dissecting the data into 10 modules. 
Finally, pathway enrichment analysis of genes within modules was performed using 
the ‘findmotifs.pl’ function of HOMER. Correction for multiple comparisons for 
KEGG pathway analyses was performed using the STATS package of R and applying 
Benjamini-Hochberg correction. To focus on the most important molecular pathways, 
only pathways with logP ≤ -3 and at least 5 genes were considered. 
 
Chromatin Immunoprecipitation, library preparation and analysis 
For microglia isolation for chromatin purification, 1 mM sodium butyrate, an inhibitor 
of histone deacetylases31, was added to the dissection medium and FACS buffers. 
After staining, microglia were fixed in 1% PFA for 10 minutes at room temperature, 
followed by addition of glycine (final concentration: 125 mM) for 5 minutes and 
washing in HBSS. Microglia were then sorted into homogenisation buffer (0.32 M 
sucrose, 5 mM CaCl2, 5 mM MgAc2, 50 mM HEPES, 0.1 mM EDTA, 1 mM DTT, 
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0.1% vol/vol Triton-X-100) and centrifuged at 950 g for 5 minutes at 4 °C. The pellet 
was resuspended in 100 µl Nelson buffer (50 mM Tris, 150 mM NaCl, 20 mM EDTA, 
1% vol/vol Triton-X-100, 0.5% vol/vol NP-40) and frozen on dry ice. 
ChIP-sequencing was performed as previously described51, with slight modifications. 
In brief, two biological replicates were analysed for each condition and targeted 
histone modification. Cell lysates from 8-10 mice were pooled giving a total cell 
number of approximately 0.8-1 million cells per replicate. The cross-linked chromatin 
was sheared for 3x7 cycles (30 sec. On/Off) in a BioruptorPlus (Diagenode) to 
achieve an average fragment size of 350 bps. Proper shearing and chromatin 
concentration was validated by DNA isolation and quantification using a small 
amount of each sample individually. Samples were split in half and 1 µg of ChIP-
grade antibody (H3K4me1: Abcam ab8895 or H3K27ac: Abcam ab4729) was added 
and incubated overnight at 4ºC. From each sample, 1% of the total volume was taken 
as input control prior to antibody binding. Immunoprecipitation was performed by 
incubating samples with 30 µl BSA-blocked protein A magnetic beads (Dynabeads, 
Invitrogen) for 1h at 4ºC. After purifying the precipitated chromatin and isolating the 
DNA, DNA libraries were generated using the Next Ultra DNA Library Prep Kit for 
Illumina and the Q5 polymerase (New England Biolabs). Multiplexing of samples 
was done using 6 different index-primers from the Library Prep Kit. For each 
replicate, samples from each condition (genotype and treatment) were pooled to rule 
out amplification and sequencing biases within the final data. Input samples were 
pooled and processed accordingly. The ideal number of amplification cycles was 
estimated via RealTime PCR to avoid over-amplification. Accordingly, samples were 
amplified for 13-15 cycles and the DNA was isolated afterwards. Individual libraries 
were pooled whereby each pool represented one whole batch of samples for each 
condition and targeted histone modification and was set to a final DNA concentration 
of 2 nM before sequencing (50 bp) on a HiSeq 2000 (Illumina) according to the 
manufacturer's instructions. 
Base calling from raw images and file conversion to fastq files was achieved by 
standard Illumina pipeline scripts. Sequencing reads were then mapped to mouse 
reference genome (mm10) using rna-STAR aligner v2.3.0 with non-default 
parameters. Data were further processed using HOMER software 
(http://homer.salk.edu/homer/), following two recently published analyses on 
microglial epigenetic profiles31,32. Tag directories were created from bam files using 
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‘makeTagDirectory’ for individual samples and inputs, and peak calling was 
performed using ‘findpeaks -style histone’ with 4-fold enrichment over background 
and input, a Poisson p-value of 0.0001, and a peak width of 500 bp for H3K4me1 and 
250 bp for H3K27ac. Peaks common to both replicates were determined using 
‘mergepeaks’ (-prefix) function. To focus analysis on enhancers, peaks within ±2.5 kb 
of known TSS were filtered out. Union peak files for H3K4me1 and H3K27ac marks 
were then created for group-wise comparisons using ‘mergepeaks’ function. Active 
enhancers, i.e. genomic regions containing both H3K4me1 and H3K27ac peaks, were 
identified using the ‘window’ function of bedtools2 [52], requiring peaks of both 
marks to be located within a genomic region of 4 kb. Union peak files of active 
enhancers were then used for comparisons amongst groups for both H3K4me1 and 
H3K27ac marks using the ‘getDifferentialPeaks’ function (using a fold-change cut-off 
of 1.5 and a cumulative Poisson p-value of 0.0001). Finally, differential peaks were 
annotated using the ‘annotatepeaks.pl’ function, including gene ontology analysis. 
Correction for multiple comparisons for KEGG pathway analyses was performed 
using the STATS package of R and applying Benjamini-Hochberg correction. To 
focus on the most important molecular pathways, only pathways with logP ≤ -3 and at 
least three genes were considered. 
For the generation of UCSC browser files, the ‘makeUCSCfile’ function was used, 
including normalisation to respective input and library size, with a resolution of 10 
bp. Files for heatmaps of 24 kb genomic regions and with a resolution of 250 bp were 
generated using the ‘annotatePeaks.pl’ function; clustering was then performed using 
Gene Cluster 3.0 and visualised using JavaTreeView.  
To identify transcription factors involved in the differential activation of enhancers, 
the ‘findMotifsGenome.pl’ command was used to analyse a region of 500 bp around 
enhancer peaks (-size 500), as this resulted in more robust identification of motifs for 
known microglial lineage-determining transcription factors when determining motifs 
of all identified microglial enhancers (Extended Data Fig.8). For all active enhancers, 
motif analysis was performed using the union H3K27ac peak file and standard 
background (i.e. random genomic sequence created by HOMER). In the case of 
pairwise comparisons amongst conditions, the first condition’s specific H3K27ac 
peak file was used as input and the second condition’s peak file as background. 
Because motif enrichment was often relatively low, we focussed on the most relevant 
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results by determining transcription factor (families), whose motifs occurred at least 
twice in ‘known’ and ‘de-novo’ motifs.  
 
Comparison between enhancer activation and gene expression 
From our 14 pairwise comparisons (Fig.4, Extended Data Fig.7 and Supplementary 
Table 2), we analysed 772 differentially activated enhancers and compared 
increased/decreased H3K27ac levels with the direction of change in the expression of 
the nearest gene (difference in z-scores between the groups used for pairwise 
comparisons). The 14 concordance values were then statistically compared to chance 
level (50%) using a two-tailed Wilcoxon signed rank test. 
 
Statistics and Reproducibility 
Statistical analyses were performed using IBM SPSS Statistics 22 or Prism 5 
software. Data were assessed for normal distribution (Shapiro-Wilk test) and 
statistical outliers using the ‘explore’ function. If the normality criterion was met, data 
were analysed using a one-way ANOVA (for experiments on single genotypes), 
followed by pairwise comparison (if P<0.05) with post-hoc Tukey correction (for 
samples with non-significant homogeneity of variance Levene’s test) or Dunnett test 
(if homogeneity of variances not given). For comparisons across treatments and 
genotypes (e.g. cytokine analyses in Fig.2), a two-way ANOVA was performed, 
followed by posthoc testing with Tukey correction for significant main effects 
(P<0.05). As the cytokine data for acute LPS stimulation (Fig.1) showed inequality of 
variance as well as skewedness, a non-parametric independent-samples median test 
was performed followed by pairwise comparison with correction for multiple 
comparison.  
All experiments were performed at least twice and in independent batches of animals 
for key findings (figures show the pooled data). Due to batch-related variation in 
some dependent variables, ‘batch’ was added as a random variable to analyses where 
a significant batch effect was observed. For data sets with small sample size (e.g. 
Western Blotting analyses), the Kruskal-Wallis test was performed, followed by 
pairwise comparisons if P< 0.05. In the figure legends ‘n’ denotes the number of 
animals per treatment group. Minimum sample sizes were determined a priori using 
power analyses or as dictated by the methodology (e.g. ChIP-Seq).  
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Raw and processed data are provided in the Gene Expression Omnibus (accession 
number GSE82170; subseries GSE82168 for ChIP-Seq and GSE104630 for RNA-Seq 
datasets). Other data that support the findings of this study are available from the 
corresponding author upon reasonable request. 
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Extended Data Figure 1: Acute responses to LPS injections.  
a, Weight changes after injection of lipopolysaccharides (LPS) (wildtype animals: n=11,11,11,11,4 
for PBS, n=9,9,9,8,7 for 1xLPS, n=10,10,10,10,7 for 4xLPS; APP animals: n=14,14,14,14,7 for 
PBS, n=8,8,8,5,5 for 1xLPS; n=10,10,10,10,10 for 4xLPS; Cre animals n=5,5,4). b/c, 
Morphological changes in microglia (n=6,6,6,6,6 animals). Scale bar: 50 µm. d, Numbers of 
microglia and activated (GFAP+) astrocytes (microglia n=6,7,8,6,6 animals, astrocytes n=6,8,9,7,5 
animals). e, Blood and brain levels of LPS after daily injections with 500 µg/kg bodyweight 
(n=4,3,3,3,3 animals). f, Assessment of iron entry from the blood (detected by Prussian Blue 
staining) shows positive staining in an aged (>25 months) APP transgenic animal, but not after 
repeated intraperitoneal LPS injections (n=3 mice analysed). g, In mice expressing red fluorescent 
protein (RFP) under the 'type 2 CC chemokine receptor’ (Ccr2) promoter, no entry of CCR2-
expressing blood monocytes is detected after repeated LPS injection (staining for RFP; insert shows 
RFP-positive monocytes in the choroid plexus; n=3 mice analysed). Scale bar: 100 µm. Data are 
means±s.e.m. */**/*** P  <0.05/0.01/  0.001 for one-way ANOVA with Tukey correction.  
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Extended Data Figure 2: Cytokine response after acute LPS injections. 
a, Additional cytokines (cp. Fig.1) analysed in the serum (top) and brain (bottom) 3h after each 
daily intraperitoneal lipopolysaccharide (LPS) injection on four consecutive days in 3-month-old 
mice (control animals received PBS injections; n=16,11,12,9,9,7,7 | 5,13,4,6,9,4,5 mice for groups 
from left to right). b/c, Cytokine response in the blood only in wildtype (b, n=6,7,8,5,5,3,3 animals) 
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or APP23 (c, n=10,3,3,3,4,3,3 animals) mice. d/e, Cytokine response in the brain only in wildtype 
(d, n=6,7,8,5,5,3,3 animals) or APP23 (e, n=10,4,4,4,4,4,4 animals) mice. Data are means± s.e.m. 
*/**/*** P  <0.05/0.01/  0.001 for independent-samples median test with correction for multiple 
comparisons. 
 
Extended Data Figure 3: APP levels and processing, neuritic dystrophy and astrocyte 
activation in 9-month-old APP23 animals. 
a/b, Micrograph of fluorescent staining for amyloid plaque (Methoxy-X04; green) and amyloid 
precursor protein (APP; red) shows neuritic dystrophy surrounding the amyloid deposit, which is 
unchanged by LPS treatments (b; n=5,5,5 animals). c, Overall Pearson’s correlation of plaque size 
with neuritic dystrophy (‘APP area’; n=49,39,42 plaques for PBS/1xLPS/4xLPS groups). d, 
Western Blotting analysis (for gel source data, see Supplementary Figure 1) of brain homogenates 
for amyloid precursor protein (APP) and C-terminal fragment-β (CTFβ; n=7,4,7 animals), and 
soluble APPβ ELISA (n=6,6,6 animals). e, Micrograph of activated astrocytes (glial fibrillar acidic 
protein: GFAP) surrounding an amyloid plaque (Congo Red) and quantification of the number of 
plaque-associated GFAP-positive astrocytes (n=6,6,5 animals). Scale bar: 10 µm in (a), 20 µm in 
(e). Data are means±s.e.m. * P  <0.05 for one-way ANOVA with Tukey correction. 
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Extended Data Figure 4: Cytokine levels in 9-month-old animals  
a, Cytokine measurements in brain homogenates of 9-month-old wildtype (n=8,8,7 animals) and 
APP23 (n=14,10,10 animals) mice treated i.p. with 1x or 4xLPS at 3 months of age. b, Cytokine 
measurements in the serum of 9-month-old wildtype (WILDTYPE; n=14,9,13 animals) and APP23 
(APP; n=18,12,14 animals) mice after i.p. stimulation with 1x or 4xLPS at 3 months of age. c, 
Cytokine measurements in the serum of wildtype animals stimulated i.p. with 1x or 4xLPS at 3 
months of age and re-stimulated with an additional LPS injection (500 µg/kg) at 9 months of age 
(n=10,7,10 animals). Data are means±s.e.m. */** P  <0.05/0.01 for two-way ANOVA with Tukey 
correction. In (b) a significant main effect for genotype is indicated by bars spanning all conditions 
of the same genotype.  
 
Extended Data Figure 5: Cytokine levels after brain ischemia and in blood of 4-month-old 
animals. 
Three-month-old animals were i.p. injected with 1x or 4xLPS and incubated for 4 weeks before 
receiving a stroke. a, Cytokine measurements in brain homogenates 24h after stroke (n=5,7,5,5 
animals). b, Cytokine measurements in the serum (n=6,6,6 animals). Data are means±s.e.m. *** 
P<0.001 for one-way ANOVA with Tukey correction. 
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Extended Data Figure 6: Microglial sorting strategy.  
Microglia were sorted as CD11bhigh and CD45low cells (population P4) from 9-month-old APP23 
animals or wildtype littermates following i.p. injections of 1x or 4xLPS at 3 months of age.  
 
Extended Data Figure 7: Analysis of microglial enhancers.  
Microglial enhancers were analysed in 9-month-old wildtype and APP23 (APP) mice treated 
intraperitoneally with 1x or 4xLPS at 3 months of age. a, Exemplary UCSC browser images of 
genomic region around the Hif1a gene (normalised to input and library dimension). b, Numbers of 
regions with differentially regulated H3K4me1 levels. c, Heatmaps of H3K4me1 regions (centred 
on H3K27ac peaks). d, Pairwise correlations between the two replicates of H3K4me1 read densities 
in differentially regulated regions. e-g, Analyses of H3K27ac levels analogous to (b-d) for 
H3K4me1. n=2 replicates (8-10 animals/replicate); differential enhancers showed a cumulative 
Poisson P-value <0.0001; Benjamini-Hochberg correction was applied for pathway enrichment. 
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Extended Data Figure 8: Transcription factor motif analysis of active enhancer regions.  
Motif analysis was performed for selected conditions to identify transcription factors involved in 
the differential activation of enhancers (using putative enhancer regions present in both replicates 
within 500 bp around enhancer peaks). a, For all active enhancers, motif analysis was performed 
using the union H3K27ac peak file and standard background (random genomic sequence). b, 
Pairwise comparisons between conditions, using the first condition’s H3K27ac peak file as input 
and the second condition’s peak file as background. As motif enrichment was often relatively low, 
the analysis was focussed on transcription factor (families), whose motifs occurred at least twice in 
‘known’ (black) and ‘de-novo’ motifs (blue). Motifs are identified by HOMER software using 
hypergeometric testing (no adjustment for multiple comparisons was made).  
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Extended Data Figure 9: Peripherally applied cytokines induce immune memory in the brain. 
a, Experimental design. b, Cytokine responses in the brain, four weeks after peripheral cytokine 
application (n=17,5,5,21,8,8,15 animals). Note that TNF-α dose-dependently enhances (low dose) 
or decreases (high dose) certain cytokines. Similar to high dose TNF-α, certain cytokines are also 
reduced by peripheral application of IL-10 four weeks earlier. c, Cytokine responses in the 
periphery are unaffected (n=8,21,9,5,10 animals). Data are means±s.e.m. */**/*** 
P<0.05/0.01/0.001 for one-way ANOVA with Tukey correction.  
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Abstract 
Microglia, the resident parenchymal macrophages of the brain, adopt a variety of 
phenotypes in health and disease. Whether their role in Alzheimer’s disease is 
beneficial or detrimental for disease progression is still under debate. A protective 
function of microglia in the compaction of amyloid-β plaques has recently been 
described. Here, we stimulated pre-depositing APP23 mice peripherally with 
lipopolysaccharide (LPS), which we have previously shown to induce training 
(1xLPS) or tolerance (4xLPS) of the inflammatory response in the brain and 
differentially modulate cerebral β-amyloidosis. Using amyloid conformation-sensitive 
dyes, we herein demonstrate alterations in plaque structure 9 months after 1xLPS and 
4xLPS treatment. While no other alterations in Aβ pathology were detectable in 12 
months old APP23 mice, number and phenotype of plaque-associated microglia were 
differentially modulated by peripheral immune stimulation. Both 1xLPS and 4xLPS 
resulted in long-term microglial barrier impairment, precipitating less compacted 
plaques associated with increased neuronal damage. Our study suggests a role of the 
individual peripheral inflammatory status in shaping amyloid plaque structure in the 
brain and demonstrates that systemic inflammatory events lead to long-lasting 
impairment in microglial barrier function associated with increased neurotoxicity. 
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Introduction 
It is now well accepted that many neurological diseases present with a strong immune 
component. For Alzheimer’s disease (AD), the link between the immune system and 
disease pathogenesis was highlighted by the identification of risk variants in immune-
related genes by large genome-wide association studies (Gagliano et al., 2016; 
Guerreiro et al., 2013; Hollingworth et al., 2011; Huang et al., 2017; Lambert et al., 
2013; Naj et al., 2011; Sims et al., 2017; Zhang et al., 2013). Many of the disease-
associated immune proteins such as Pu.1, CD33, complement receptor 1, and Trem2 
are expressed in microglia, the brain’s resident parenchymal macrophage population. 
Microglia participate in a variety of developmental and homeostatic processes in the 
brain and can acquire a broad spectrum of phenotypes characterized by differential 
transcriptional profiles (Gomez-Nicola & Perry, 2015; Keren-Shaul et al., 2017; 
Krasemann et al., 2017; Mathys et al., 2017; Ransohoff & Perry, 2009). Their 
contribution to the onset and progression of AD has been intensely studied and 
resulted in many conflicting reports about the effects of immune system modulation 
on disease progression (Chakrabarty et al., 2015; Heneka et al., 2013; Jay et al., 2017; 
Kitazawa et al., 2011; Shi et al., 2011; Vom Berg et al., 2012), possibly due to 
cellular heterogeneity of immune cells in the brain. Single-cell sorting followed by 
transcriptional profiling has demonstrated strong heterogeneity in microglial 
expression profiles and identified molecular pathways activated in a subtype of 
microglia (termed disease-associated microglia – DAM, or microglia 
neurodegenerative phenotype – MgnD) under neurodegenerative disease conditions 
(Keren-Shaul et al., 2017). In Alzheimer’s disease, microglia localized in close 
proximity to amyloid-β (Aβ) plaques differ in gene expression from plaque-distant 
microglia (Keren-Shaul et al., 2017; Krasemann et al., 2017). Recent studies 
described the compaction of amyloid plaques as a previously unappreciated function 
of plaque-associated microglia (Condello et al., 2015; Wang et al., 2016; Yuan et al., 
2016). Importantly, a change in the microglial activation state as a result of CX3CR1 
or Trem2 knockout altered the structure and density of amyloid plaques. This, in turn, 
enhanced neurotoxicity, as evidenced by increased neuritic dystrophy and 
hyperphosphorylated tau around plaques.  
Microglia are exceptionally long-lived cells with a median lifetime close to 24 months 
(equivalent to the lifespan of a mouse) in the cortex (Mai et al., 2017, Füger et al., 
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2017). These data indicate that at least a part of the microglial population persists for 
the entire lifetime of an animal. This is particularly important since microglia are 
sensitive to perturbations reaching the brain environment, including systemic 
inflammation (Cunningham, 2013; Perry et al., 2007). We have recently shown that 
microglial stimulation results in modification of their epigenetic profile, which 
persists for many months, and subsequently modifies microglial responses to brain 
pathology, including Aβ deposition (Wendeln & Degenhardt et al., 2018). In 
particular, we found that peripheral immune stimulation of APP23 mice, a mouse 
model for cerebral β-amyloidosis (Sturchler-Pierrat et al., 1997), before onset of Aβ 
deposition differentially modulated the amount of amyloid pathology 6 months later 
(Wendeln & Degenhardt et al., 2018).  
In the present study, we further investigate whether microglial reprogramming before 
the onset of cerebral β-amyloidosis would subsequently affect the structure and 
neurotoxicity of amyloid plaques. To this end, we again applied single (1x) or 
repeated injections (4x) of lipopolysaccharide (LPS) to pre-depositing APP23 mice, 
which we have previously found to cause a heightened or reduced immune response 
to cerebral β-amyloidosis (also referred to as “training” and “tolerance”). Those two 
injection paradigms led to long-lasting alterations of the microglial epigenetic and 
transcriptional landscape, resulting in differential modification of plaque load upon 
early amyloid deposition. Here, we use the same injection paradigms to analyze 
whether a change in the microglial phenotype would alter amyloid plaque maturation, 
thereby affecting amyloid-associated neurotoxicity. Using a set of conformation-
sensitive amyloid-binding dyes, the luminescent conjugated oligothiophenes (LCOs, 
(Klingstedt et al., 2011), we show that both 1xLPS and 4xLPS injections at 3 months 
of age altered microglial features and thereby led to changes in plaque morphology 
and increased amyloid-associated neuritic dystrophy. These results confirm the 
protective nature of the microglial barrier function for the structural compaction of 
amyloid plaques and demonstrate that this function can be permanently impaired by 
systemic inflammation occurring much earlier in life.   
  
 116 
Methods 
Animals 
For all experiments, 3 month-old hemizygous APP23 transgenic (C57BL/6J-
Tg(Thy1-APPK670N;M671L)23) were used (Sturchler-Pierrat et al., 1997). APP23 mice 
express human amyloid-β precursor protein (APP) with the Swedish double mutation 
under the Thy-1 promoter, and have been backcrossed to C57BL/6J mice for >20 
generations. Only female mice were used for experiments due to the described 
significant gender effect on the pathology of cerebral β-amyloidosis (Sturchler-Pierrat 
& Staufenbiel, 2000). In the neocortex, female mice develop the first amyloid plaques 
around 6 months of age (Sturchler-Pierrat et al., 1997).  
All animals were maintained under specific pathogen-free conditions and were housed 
in groups with enrichment. All experiments were performed in accordance with the 
veterinary office regulations of Baden-Württemberg (Germany) and were approved 
by the Ethical Commission for animal experimentation of Tübingen, Germany. 
 
Peripheral immune stimulation 
Female APP23 mice were randomly assigned to treatment groups and were injected at 
the specified time points (3 months or 7 months) intraperitoneally (i.p.) with LPS 
(from salmonella enterica serotype typhimurium, Sigma) at a daily dose of 500 µg/kg 
bodyweight. On four consecutive days, animals received either four LPS injections 
(4xLPS), or four vehicle injections (phosphate buffered saline, PBS), or a single LPS 
injection followed by three vehicle injections on the following three days (1xLPS). 
At the specified time-points (6, 9, or 12 months of age), animals were deeply 
anaesthetised using sedaxylan/ketamine (64 mg/kg//472 mg/kg). Blood was collected 
from the right ventricle of the heart, followed by trans-cardial perfusion with ice-cold 
PBS through the left ventricle. The brain was removed and sagitally separated into the 
two hemispheres, which were either fixed in 4% paraformaldehyde (PFA) or fresh 
frozen on dry ice. Fresh frozen hemispheres were homogenised using a Precellys® 
lysing kit and machine at 20% (w/v) in homogenisation buffer (50 mM Tris pH 8, 150 
mM NaCl, 5 mM EDTA) containing phosphatase and protease inhibitors (Pierce). 
Fixed hemispheres were kept in 4% PFA for 24 h, followed by cryoprotection in 30% 
sucrose in PBS, and subsequently frozen in 2-methylbutane. For histological analysis, 
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fixed brain hemispheres were coronally sectioned at 25 µm using a freezing-sliding 
microtome (Leica).  
 
Immunostaining 
Immunohistochemical stainings were performed on free-floating sections using either 
Vectastain Elite ABC kits (Vector laboratories) or fluorescent secondary antibodies 
(Jackson Immunolaboratories). If LCO costaining was desired, fluorescent secondary 
antibodies coupled to Alexa-647 were used for detection of the protein of interest, 
followed by staining with quadro-formyl thiophene acetic acid (qFTAA) and hepta-
formyl thiophene acetic acid (hFTAA) (see below).  
Brain sections were blocked for 1 h with 5% normal serum of the secondary antibody 
species, followed by primary antibody incubation overnight at 4°C. Primary 
antibodies used were: rabbit anti-Pu.1 (1:1,000; Cell Signaling), rabbit anti-Iba1 
(1:1,000; Wako), rabbit anti-Aβ (NT12; courtesy of P. Paganetti, Basel, Switzerland), 
rat anti-CD68 (1:1,000; Serotec), sheep anti-Trem2 (1:100; R&D systems), rabbit 
anti-APP (5313, 1:750; generous gift from C. Haas, Munich), and rabbit anti-GFAP 
(1:500, Biozol). Congo Red staining was conducted according to standard procedures. 
Immunohistochemical images were acquired on an Axioplan 2 microscope; colour 
images were captured using an Axioplan MRc camera and AxioVision 4.7 software 
(Carl Zeiss). Fluorescence images were acquired using an LSM 510 META (Axiovert 
200M) confocal microscope with an oil immersion x40/1.3 objective and LSM 
software 4.2 (Carl Zeiss). Sequential excitation of fluorophores ensured no 
fluorescence cross-talk and best signal throughput. Maximum-intensity projections 
were generated using IMARIS 8.3.1 software (Bitmap) or Fiji.  
 
LCO staining and spectral imaging 
Free-floating sections were stained with the LCOs qFTAA (1.5 mM in deionized 
water, diluted 1:500 in PBS) and hFTAA (1.5 mM in deionized water, diluted 1:1000 
in PBS for double stain with qFTAA, 1:500 in PBS for single stain) for 30 minutes. 
After mounting, sections were dried and coverslipped with Fluorsave mounting 
medium (Calbiochem).   
Spectra of qFTAA- and hFTAA-stained amyloid aggregates were acquired on a Zeiss 
LSM 510 META (Axiovert 200M) confocal microscope equipped with a spectral 
detector with an oil-immersion x40/1.3 objective. The dyes were excited using the 
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458 nm argon laser line. Emission spectra were acquired from 470 to 695 nm with 
steps of 10.7 nm at 3 different regions of interest (ROIs) within the middle core region 
from an intermediate plane of each plaque. Acquired plaques originated from at least 
three different sections throughout the mouse brain. The mean emission spectrum per 
plaque was calculated from the 3 ROIs and normalized to its respective maxima. The 
ratio of the intensity of emitted light at the qFTAA peak (502 nm) and the hFTAA 
peak (588 nm) was used as readout for spectral distinction of plaques. For 12 months 
old APP23 animals, the 502 / 588 nm ratio was calculated for statistical analysis from 
the normalized mean spectrum generated from at least 35 plaques per animal. Figure 1 
shows pooled data from all PBS-injected control animals independent of injection 
time point.  
For 9 months old APP23 animals, single staining with hFTAA was conducted and the 
emission spectrum of 20-30 plaques per animal was acquired and processed as 
described. The ratio of the intensity of emitted light at the two local emission maxima 
(545 nm and 588 nm) was used as readout for spectral distinction of plaques. 
 
Image quantification 
For quantification of mean plaque area and Congo red positive area, mosaic images of 
5 consecutive sections stained immunohistochemically for NT12 and Congo red were 
acquired on a Zeiss Axioplan 2 microscope with a x4/0.1 objective. Image analyses 
were automated using custom-written plugins in Fiji. Quantification of the mean 
plaque area was performed in the neocortex using the luminance channel. If needed, 
the gamma value was adjusted to ensure uniform contrast between staining and 
background. A fixed manual threshold was determined so that plaques were above 
threshold and was applied to all images. Staining of cerebral amyloid angiopathy and 
areas with high background staining were excluded from analysis. Only plaques with 
a minimum size of 30 µm2 were included in the analysis. Automatic recognition of 
plaques was manually checked and corrected upon misclassification. The Congo red 
positive area was quantified by transforming the RGB image to the CIELAB colour 
space and subsequently thresholding the positive values of the a* channel, which 
designates the purity of the red colour. 
To quantify neuronal dystrophy, and microglial expression of Iba1, Trem2, and 
CD68, 5-10 fluorescent images per animal (APP: 7-44 plaques per animal, on average 
22 plaques; Iba1: 6-55 plaques per animal, on average 22 plaques; CD68: 9-31 
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plaques per animal, on average 21 plaques; Trem2: 10-42 plaques per animal, on 
average 23 plaques) were acquired with the same microscope settings. Detection of 
qFTAA and hFTAA was achieved using bandpass filters encompassing their 
respective maximum emission wavelength. Images were subsequently semi-
automatically analysed with another custom plugin written in Fiji. Maximum intensity 
projections were generated to choose the region of interest consisting of the plaque 
with the desired staining. Fluorescence channels were split and fixed intensity 
thresholds were applied to each channel. For every plaque, plaque size and area of the 
costained protein within the region of interest were determined based on thresholded 
areas. Plaques smaller 100 µm2 or bigger 2500 µm2 were excluded from analysis. The 
area of the protein of interest was divided by plaque size for normalization purposes. 
To analyse colocalization between the protein of interest and the amyloid plaque, the 
same images were analysed in IMARIS. Using the 3D colocalization tool, a constant 
threshold was applied to the fluorescent channels for hFTAA and the protein of 
interest. The threshold for hFTAA was determined so that the whole amyloid plaque 
(i.e. including the qFTAA positive core) was included in the colocalization analysis. 
The percentage of colocalized plaque material in relation to total plaque material per 
image was used as readout for protein colocalization.   
To assess the influence of plaque size and structure on neuronal dystrophy, acquired 
images from PBS-treated 12 months old APP23 controls were semi-automatically 
analyzed with a custom plugin written in Fiji. Maximum intensity projections were 
generated to choose the region of interest consisting of the plaque with the 
surrounding APP staining. For every plaque, a core region was chosen, wherein the 
intensity of qFTAA and hFTAA was subsequently measured. Fluorescence channels 
were split and fixed intensity thresholds were applied to each channel. Based on 
thresholded areas, plaque size and the ratio of qFTAA intensity to hFTAA intensity in 
its core were determined for every plaque (core qFTAA / hFTAA ratio), in addition to 
the area of surrounding APP staining. These data were generated for 192 plaques of 
11 PBS-treated APP23 control mice and subsequently analyzed using JMP 13.0.  
 
Stereological quantification 
Stereological quantification was performed by a blinded observer on random sets of 
every 12th systematically sampled 25 µm thick sections throughout the neocortex. 
Analysis was conducted with the Stereologer software (Stereo Investigator 6; MBF 
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Bioscience) and a motorized x-y-z stage coupled to a video microscopy system 
(Optronics). For quantification of microglial numbers based on Pu.1 staining, the 
optical fractionator technique was used with three-dimensional dissectors as 
previously described (Varvel et al., 2015). The number of plaque-associated GFAP- 
and Pu.1-positive cells was determined for at least 30 plaques per animal. Plaque load 
was determined using the area fraction fractionator technique (Bondolfi et al., 2002) 
based on Congo Red and anti-Aβ staining (NT12 antibody).  
 
ELISA 
For quantification of Aβ by ELISA, brain homogenates were pretreated with formic 
acid (Sigma-Aldrich, final concentration: 70% vol/vol), followed by sonication for 30 
seconds on ice, and subsequent centrifugation at 25,000 g for 1 hour at 4°C. 
Supernatants were equilibrated in neutralization buffer (1 M Tris base, 0.5 M 
Na2HPO4, 0.05% NaN3 (wt/vol)). Aβ was measured using human (6E10) Aβ triplex 
assay (Meso Scale Discovery, MSD) according to the manufacturer’s instructions. 
Total Aβ was calculated as the sum of the measured values for Aβ1-38, Aβ1-40, and 
Aβ1-42. 
For cytokine measurements, brain homogenates were centrifuged at 25,000 g for 30 
minutes at 4 °C. Supernatants were analyzed with mouse pro-inflammatory panel 1 V-
plex plate (MSD) according to the manufacturer’s instructions. To determine blood 
cytokines, serum was obtained by coagulation of whole blood in Vacuettes (Greiner 
Bio-One) for 10 min at room temperature, followed by centrifugation for 10 min at 
2,000 g. Serum samples were diluted 1:2 before cytokine measurement. The 
investigator was blinded to treatment groups.  
Measurements were performed on a Mesoscale Sector Imager 6000 and data were 
analyzed using MSD discovery workbench software 2.0. For brain homogenates, 
cytokine levels were normalised against total protein amount as measured by 
microplate Pierce bicinchoninic acid (BCA) protein assay (Perbio Science).  
 
Western Blotting analysis 
For Western Blotting, Urea was added at a final concentration of 5.4 M to total brain 
homogenates. Samples were incubated for 10 minutes at 70°C, followed by 
centrifugation for 1 minute at 16000 g. Pellets were discarded and protein levels of 
the supernant were quantified with a microplate Pierce 660 nm protein assay (Thermo 
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Fischer) and adjusted to equal protein concentrations. After addition of Urea sample 
buffer (final concentration: 10% glycerol (vol/vol), 2% SDS (wt/vol), 0.0002% 
Bromphonel blue, 0.1M Tris-HCL (pH 8.6), 2% β-mercaptoethanol (vol/vol)) 15 µg 
total protein per sample were analysed on BOLT 4-12% Bis-Tris gels (Thermo 
Fischer) using standard procedures. Proteins were transferred to nitrocellulose 
membranes, followed by boiling of the membranes for 5 minutes in a microwave. 
Ponceau S staining was conducted to verify equal protein transfer across samples. 
Blocking was performed with 5% milk in phosphate buffered saline containing 0.05% 
Tween (PBST) for 1h and blots were incubated with the following primary antibodies: 
mouse anti-Aβ (6E10; 1:2500, Covance Research Products), mouse anti-GAPDH 
(1:106, Acros Antibodies) in PBST overnight at 4°C. Membranes were then probed 
with the respective secondary HRP-labelled antibodies (1:20,000, Jackson 
ImmunoLaboratories). Protein bands were detected using chemiluminescent 
peroxidase substrate (ECL prime, GE Healthcare). Densitometric values of protein 
band intensities were determined in Fiji and normalised to GAPDH intensities. 
Samples were analysed at least three times on separate blots. The mean value of 
normalised intensities of all technical replicates per sample is shown and was used for 
statistical analysis.  
 
Statistical analysis 
To assess the influence of plaque size and structure on the amount of neuritic 
dystrophy, a dataset comprising 192 plaques of 12 months old APP23 control mice 
was analysed in JMP 13.0. Plaque area and APP area were log10 transformed to 
achieve normal distribution of data. An analysis of covariance (ANCOVA) was 
performed using the ‘Fit model’ tool with log10-transformed APP area as the 
dependent variable, and log10-transformed plaque area and core qFTAA / hFTAA 
ratio as independent variables.   
All other statistical analyses were performed using Prism 6. Data were assessed for 
normal distribution (Shapiro-Wilk test) and statistical outliers (ROUT method, Q = 
0.5%). The Brown-Forsythe test was used to check equality of variances. If the 
normality criterion was met and variances were not significantly different, data were 
analysed using a one-way ANOVA, followed by pairwise comparison (if P<0.05) 
with post-hoc Tukey correction. For data sets with small sample size, non-normally 
distributed data, or groups with unequal variances, the Kruskal-Wallis test was 
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performed, followed by pairwise comparisons (if P< 0.05) with post-hoc Dunn’s 
correction. For comparisons between two groups, two-tailed Mann Whitney test was 
performed. All experiments were at least performed twice or in independent batches 
of animals (figures show the pooled data). Data are presented as mean ± standard 
error of the mean (SEM). In the figure legends, ‘n’ denotes the number of animals per 
treatment group.  
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Results 
Pre-depositing 3 months old APP23 mice were stimulated with either a single 
injection of LPS followed by three vehicle injections (1xLPS) or repeated injections 
of LPS on 4 consecutive days (4xLPS). We have recently shown that these stimuli 
induce long-lasting alterations of microglial function, with 1xLPS increasing 
microglial pro-inflammatory activity (e.g. enhancing glycolysis), and 4xLPS inducing 
a tolerant microglial state with reduced pro-inflammatory cytokine release and 
enhanced Aβ phagocytosis (Wendeln & Degenhardt et al., 2018). APP23 mice 
develop the first cerebral Aβ deposits around 6 months of age and were analyzed at 12 
months of age to determine the effect of systemic immune stimulation on plaque 
maturation. To this end, we employed staining with LCOs, a set of fluorescent 
amyloid-binding dyes that show changes in their emission spectrum upon binding of 
different amyloid structures (Aslund et al., 2009; Klingstedt et al., 2011). Costaining 
with two LCOs, qFTAA and hFTAA, followed by spectral imaging has previously 
been used to discriminate different amyloid plaque structures in human AD cases 
(Rasmussen et al., 2017). While hFTAA stains both early prefibrillar states and 
mature Aβ fibrils, qFTAA resembles Thioflavin S in its binding affinity for mature 
Aβ fibrils in the dense core of plaques (Klingstedt et al., 2011). Determining the ratio 
of emission intensities at the respective maxima of qFTAA and hFTAA (502 nm and 
588 nm, respectively) in the plaque core has emerged as a useful readout for the 
spectral distinction of Aβ plaques (Rasmussen et al., 2017). 
Strikingly, LCO staining revealed significant alterations of the amyloid plaque 
structure after 1xLPS and 4xLPS treatment. While 12 months old APP23 control mice 
(PBS treated) contained a heterogeneous mixture of plaque structures, LPS-treated 
animals predominantly demonstrated plaques with strongly reduced qFTAA staining 
(Figure 1a-d), indicating a shift in plaque morphology in response to peripheral 
immune stimulation 9 months earlier. Of note, both intra- (data not shown) and inter-
individual variability in plaque structure was reduced after LPS treatment, 
demonstrating that systemic inflammation led to a shift from naturally occurring 
heterogeneity to predominance of one plaque structure (Figure 1b-d). These effects of 
peripheral LPS stimulation were absent in APP23 animals that were peripherally 
stimulated with LPS shorter before analysis (Supplementary Figure 1a-b), i.e. at 
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7 months of age, indicating that changes in plaque morphology require long 
incubation times and do not occur as an immediate result of LPS injection.  
Changes in amyloid plaque structure after immune stimulation at 3 months were also 
detectable earlier in pathology when immature Aβ fibrils predominate in APP23 mice. 
Prior to the age of 12 months, amyloid plaques show no binding affinity for qFTAA 
(Nyström et al., 2013); however, hFTAA staining followed by spectral analysis can 
be used to assess structural differences in early immature Aβ fibrils. In 9 months old 
APP23 animals that were treated at 3 months with 1xLPS or 4xLPS, a significant 
change in the emission spectrum of hFTAA, as determined by the ratio of the 
emission intensities at 545 nm and 588 nm, was observed in animals treated with 
4xLPS only (Supplementary Figure 2a-b). Again, this effect was absent in animals 
stimulated with LPS at 7 months (Supplementary Figure 2c-d).    
Alterations in the structure of amyloid plaques could occur as a result of differences in 
Aβ pathology. We have previously shown that 1xLPS and 4xLPS treatment led to an 
increased (for 1xLPS) or decreased plaque load (for 4xLPS) in 9 months old APP23 
animals. However, at 12 months of age no changes in cortical plaque load, determined 
as the percentage of Aβ positive area in the cortex, were detectable after LPS 
treatment (Figure 1e), indicating that the sustained overexpression of Aβ may 
override the effect of LPS on plaque load in later stages of pathology. Accordingly, 
total brain Aβ levels were not significantly altered at 12 months in comparison to PBS 
treated control animals. Furthermore, we could not detect changes between treatment 
groups in the ratio of brain Aβ1-42 to brain Aβ1-40 (Figure 1f), excluding that different 
plaque structures occur as a result of altered proteolytic generation of Aβ isoforms. In 
addition, levels of amyloid precursor protein (APP) and C-terminal fragment (CTF-β) 
were equal between treatment groups (Supplementary Figure 3a), indicating that Aβ 
processing itself was not altered. 
The amount of qFTAA binding to amyloid plaques in APP23 animals increases with 
age as amyloid plaques grow in size and maturation of Aβ fibrils takes place 
(Nyström et al., 2013). Therefore, we analyzed the mean size of amyloid plaques and 
mean Congo red positive area (Supplementary Figure 3b), but could not detect 
significant differences among treatment groups. Analysis of 6 months old APP23 
mice that were previously stimulated with LPS at 3 months of age demonstrated equal 
plaque load and brain Aβ levels of PBS and LPS treated animals (Supplementary 
Figure 3c-e). This indicates that onset of Aβ pathology is not changed by LPS 
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stimulation, therefore excluding that structural alterations of plaques occur as a result 
of a different age of plaques.  
Since we could not find evidence for alterations in Aβ pathology other than plaque 
morphology by LPS stimulation, and because we have previously shown that the 
microglial phenotype is differentially altered after 1xLPS and 4xLPS treatment, we 
next examined whether alterations in plaque structure occur through a modulation of 
microglial responses. We therefore compared cardinal features of microglial 
activation among the different treatment groups. First, we analyzed the immune state 
in brain and periphery of 12 months old APP23 animals. While no significant 
alterations in serum cytokine levels were detectable (Supplementary Figure 4a), 
1xLPS treated animals exhibited enhanced cytokine expression of IFN-γ, IL-6, and 
IL-12 in the brain (Figure 2a), in line with previous results.  
Recent studies implicate the microglial activity state and in particular Trem2 
expression in the compaction of Aβ plaques (Condello et al., 2015; Wang et al., 2016; 
Yuan et al., 2016), therefore we analyzed microglial numbers and phenotype in LPS 
treated 12 months old APP23 mice. Stereological quantification revealed a significant 
reduction in the number of plaque-associated microglia in 4xLPS treated animals, 
while the overall number of microglia was not changed (Figure 2b). No alterations in 
the number of plaque-associated astrocytes were detectable (Supplementary Figure 
4b). Analysis of Iba1 staining revealed a reduction in the amount of plaque-associated 
Iba1-positive microglial process area after 4xLPS treatment (Figure 2c). These data 
indicate that there is a specific reduction of plaque-associated microglia after 4xLPS 
treatment at 12 months of age, possibly due to altered migration or turnover and in 
line with our previous description of a sustained suppression of microglial activation 
(tolerance) following 4xLPS treatment. The observed reduction in the number of 
plaque-associated microglia leading concomitantly to less microglial processes 
compacting the amyloid plaque in 12 months old APP23 mice could result in 
impairment of the microglial barrier function and thereby to the described alterations 
in amyloid plaque structure. The reduction in plaque-associated microglial number 
observed after 4xLPS in 12 months old APP23 mice diminishes upon injection of LPS 
at 7 months (Supplementary Figure 1c), similar to the described effects of LPS on 
plaque structure.  
Next, we analyzed microglial CD68 expression because we have previously observed 
increased Aβ phagocytosis in 4xLPS treated microglia (Wendeln & Degenhardt et al., 
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2018). CD68 marks active phagolysosomes and is activity-dependently regulated in 
microglia (Hendrickx et al., 2017; Rabinowitz et al., 1992). In 12 months old APP23 
animals, quantification revealed a significant reduction of CD68 positive area around 
plaques in 1xLPS treated animals in comparison to 4xLPS (Figure 3a-c). 
Colocalization of CD68 with amyloid plaques was significantly reduced after 1xLPS 
treatment in comparison to controls. These results indicate a reduction in phagocytic 
activity of microglia by 1xLPS, but not 4xLPS treatment.  
Microglial Trem2 has previously been implicated in the microglial barrier function, 
since Trem2-/- mice and sporadic AD cases with Trem2 R47H variant have impaired 
microglial migration to the plaques, resulting in a higher degree of diffuse amyloid 
plaques (Wang et al., 2016; Yuan et al., 2016). Therefore, we analyzed microglial 
Trem2 expression in LPS stimulated 12 months old APP23 mice. In line with 
previous studies, we found Trem2 to be specifically expressed in microglial processes 
contacting the amyloid plaque (Figure 3d). Similar to CD68, quantification of the 
Trem2 positive process area revealed a differential effect of 1xLPS and 4xLPS, with 
1xLPS treated microglia showing decreased Trem2 positive areas. Colocalization of 
Trem2 with amyloid plaques was also significantly reduced in 1xLPS treated animals 
compared to 4xLPS (Figure 3e-f), even though less plaque-associated microglia were 
observed after 4xLPS. However, colocalization analysis of constitutively expressed 
microglial Iba1 revealed no differences between treatment groups (Figure 2c), 
excluding that the differences in the analyzed phenotype-dependent microglial 
markers occur due to an impaired microglial localization to the plaques. In summary, 
microglial expression of both Trem2 and CD68 was reduced in 1xLPS animals, 
indicating a shift in microglial activity in 1xLPS, but not 4xLPS, treated animals. 
These data highlight that in line with our previous work 1xLPS and 4xLPS 
differentially modulate the microglial response to cerebral β-amyloidosis, and either 
change in the microglial activation state is sufficient to alter plaque structure in 
APP23 animals.  
According to the amyloid cascade hypothesis, aggregation of Aβ subsequently 
induces inflammatory processes and neuronal tau pathology, ultimately resulting in 
neuronal and synaptic damage (Hardy & Selkoe, 2002; Karran et al., 2011). An 
impairment in microglial barrier function, which leads to reduced compaction of 
amyloid plaques, has been shown to result in increased neurotoxic properties of 
plaques (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016). Thus, we 
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analyzed whether plaque-associated neuronal damage was altered in LPS treated 
animals. Strikingly, both 1xLPS and 4xLPS treated animals showed increased 
amyloid-associated neuritic dystrophy, as indicated by an increased area of APP-
positive dystrophic boutons around plaques (Figure 4a). Moreover, the amount of 
amyloid-associated neuritic dystrophy for individual plaques was significantly 
influenced not only by plaque size but also the qFTAA / hFTAA ratio of the plaque 
core (Figure 4b-c). Decreased qFTAA binding in the plaque core, corresponding to a 
lower grade of compactness of plaques, was associated with increased neuritic 
dystrophy, in line with the idea that the microglial barrier function is protective and 
renders plaques more inert.  
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Discussion 
We have herein demonstrated that following earlier systemic inflammation microglial 
barrier function is altered for at least 9 months in mice, leading to lasting structural 
changes of amyloid plaque deposits in a mouse model of AD. Our initial approach 
was to use two different stimuli (1xLPS and 4xLPS) whose acute and long-term 
effects on microglia we have recently characterized in 9 months old animals with 
early plaque deposition. A single injection of LPS primes microglia to respond with a 
trained, i.e. heightened, immune response to a secondary stimulus (e.g. the deposition 
of Aβ). In contrast, 4xLPS induces a long-lasting tolerant state in microglia, thereby 
altering their reaction to amyloid plaque deposition, resulting in increased microglial 
Aβ uptake and decreased plaque load in 9 months old APP23 animals. At this early 
disease stage, plaque structure is already significantly altered in 4xLPS treated 
animals, possibly due to increased phagocytic activity of tolerized microglia. 
However, the effect of LPS on plaque structure becomes more evident at more 
advanced stages of cerebral β-amyloidosis, with similar changes being observed in the 
two LPS treatment groups. This is possibly due to the maturation of plaques over 
time, enabling the use of the qFTAA/hFTAA double stain as a more sensitive readout 
for spectral discrimination of plaques. At 9 months of age, Aβ pathology is still in an 
early phase, thus a qFTAA positive core is absent in nearly all plaques. In contrast, at 
12 months of age, a substantial amount of plaques stains positive for both qFTAA and 
hFTAA, enabling a broader range of detection for changes in plaque structure. As it 
was previously shown that the microglial coverage of plaques reduces as the 
aggregates grow (Condello et al., 2015), it is also conceivable that alterations of the 
microglial barrier function have a larger impact at later stages of pathology. 
Interestingly, qFTAA binding to amyloid plaques increases with pathology as plaques 
mature, but is reduced again in animals over 20 months of age, indicative of less 
compacted plaques in aged animals (Nyström et al., 2013). A recent study suggested 
that microglial coverage of amyloid plaques decreases in aged mice, thereby reducing 
plaque compactness (Condello et al., 2015). It seems conceivable that, similar to other 
microglial functions (Hefendehl et al., 2014), the microglial barrier diminishes with 
age, thereby contributing to age-associated increased pathology.  
While both 1xLPS and 4xLPS led to similar alterations in plaque structure, this effect 
occurred through different microglia-mediated mechanisms. Our results indicate that 
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at 12 months of age 1xLPS treatment led to a change in plaque-associated microglial 
phenotype with reduced Trem2 and CD68 expression, while reduced plaque-
associated microglial numbers were present in 4xLPS treated animals. Both 
mechanisms ultimately led to an impairment of microglial barrier function, thereby 
resulting in less compacted amyloid plaque structures. Previous reports have 
demonstrated alterations in the microglial barrier function as a result of Trem2 or 
CX3CR1 deficiency (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016). Our 
results demonstrate that microglia mediated alterations of amyloid plaque structure 
are not necessarily genotype-dependent, but can also be induced by overall changes in 
the number of plaque-associated microglia following systemic inflammation. Despite 
the observed reduction of the number of plaque-associated microglia after 4xLPS, 
these animals had unaltered or even increased levels of microglial Trem2 and CD68, 
indicating that the remaining microglia may sense the loss of neighboring microglia 
and try to compensate for their lack in barrier function. At 9 months of age, numbers 
of plaque-associated microglia were not significantly altered between treatment 
groups (Wendeln & Degenhardt et al., 2018), demonstrating that the initial microglial 
reaction and migration to the developing amyloid plaques is not changed. It is likely 
that the later observed differences in microglial numbers occur as a result of long-
lasting epigenetic alterations induced by systemic LPS treatment, which could impact 
the turnover (proliferation or death rate) of microglia. So far, microglial turnover has 
only been investigated under homeostatic conditions or cerebral β-amyloidosis, but 
not in the context of systemic inflammation, which would be an interesting area to 
pursue.  
Our results are in line with our previous description of 1xLPS and 4xLPS as stimuli 
exerting differential long-lasting effects on microglia. In 9 months old animals, we 
have previously shown these long-term alterations in microglial function to be 
mediated by epigenetic reprogramming in response to immune stimulation. Since 
differential effects of the two LPS stimuli on microglia and brain cytokine release 
were still present in 12 months old APP23 mice, it seems highly likely that these 
effects are also epigenetically mediated, indicating that microglial immune memory 
persists even longer than we previously described. 
Through impairment of the microglial barrier function, both 1xLPS and 4xLPS 
treatment resulted in less compact amyloid plaques that were associated with 
increased neuritic dystrophy. These results are in line with previous reports 
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demonstrating a neuroprotective function of the microglial barrier around amyloid 
plaques (Condello et al., 2015; Wang et al., 2016; Yuan et al., 2016). Similar to these 
previous studies, we found increased neuronal damage around plaques that were less 
compacted as a result of an impaired microglial barrier.  
While we have demonstrated a beneficial effect of the tolerizing 4xLPS stimulus at an 
early stage of pathology, our present study revealed detrimental effects of both 1xLPS 
and 4xLPS on neuronal damage at a later stage of pathology. Similar stage-dependent 
effects on the pathology of cerebral β-amyloidosis have been described for knockout 
of Trem2 (Jay et al., 2017). 
Interestingly, our results indicate that the amount of neuritic dystrophy can be 
predicted as a function of plaque size and the LCO core ratio as a measure of plaque 
structure. Thereby, our results implicate LCO staining followed by spectral analysis 
as a useful indicator for the assessment of neuronal damage. Since neuronal damage is 
on a molecular level the best correlate for cognitive dysfunction in AD patients, our 
results suggest alterations in plaque structure as highly relevant for disease 
progression. 
In summary, our results demonstrate that systemic inflammation induces long-lasting 
changes in the microglial response to plaques. This effect of systemic inflammation 
becomes evident months after the acute immune response and leads via impairment of 
the microglial barrier function to alterations in amyloid plaque structure that are 
linked to the amount of amyloid-associated neuronal damage. If these mechanisms 
also occur in humans, long-lasting microglial memory of systemic inflammatory 
events could impact the structure of much later appearing amyloid plaques and 
thereby represent another microglia-mediated mechanism influencing neurological 
disease progression.   
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Figure 1: Alterations in plaque morphology after peripheral immune stimulation.	  
a, Experimental design. b, Micrographs depicting representative plaque morphologies in the 
different treatment groups after qFTAA and hFTAA staining. c, Normalized emission spectra per 
treatment group and colour coding of mean normalized emission spectra per animal. LPS treatment 
reduced inter-individual variability and shifted emission spectra to red wavelength. d, Ratio of 
emission intensities at 502 / 588 nm of the average spectrum per animal (n=22,10,11) and 
quantification of the core qFTAA/hFTAA ratio (n=12,10,10) from maximum intensity projections 
of acquired z-stacks revealed significant differences in plaque structure of 1xLPS and 4xLPS 
treated animals in comparison to controls. e, Micrograph and quantification of cortical Aβ plaque 
load (n=12,10,11) per animal. f, ELISA measurement of total Aβ levels and Aβ1-40 to Aβ1-42 ratio 
(n=13,10,11). Scale bar 10 µm. */**=p<0.05/0.01. Data are presented as mean ± SEM. 
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Figure 2: Long-term changes in brain cytokine levels and number of plaque-associated 
microglia after peripheral immune stimulation. 
a, ELISA measurement of brain cytokine levels for IFN-γ, IL-12, and IL-6 (n=8,7,9) showed 
increased amounts in 1xLPS treated animals. b, Micrograph and stereological quantification of Pu.1 
stained plaque-associated (n=8,9,10 animals) and total microglia (n=6,6,6 animals). c, 
Immunofluorescent costaining for Iba1 (red) and qFTAA (blue) / hFTAA (green), quantification of 
normalized plaque-associated Iba1 positive area, and colocalization with plaque staining 
(n=10,10,10 animals with 22 plaques per animal on average). Scale bar 10 µm. */**=p<0.05/0.01. 
Data are presented as mean ± SEM. 
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Figure 3: Alterations in microglial Trem2 and CD68 expression after systemic inflammation. 
a, Immunofluorescent staining for Trem2 showing colocalization with Iba1. b, Representative 
images of Trem2 staining in different treatment groups. c, Quantification of normalized plaque-
associated Trem2 positive area and colocalization with plaque staining (n=10,10,10 animals with 23 
plaques per animal on average). d, Immunofluorescent staining for CD68 showing colocalization 
with Iba1. e, Representative images of CD68 staining in different treatment groups. f, 
Quantification of normalized plaque-associated CD68 positive area and colocalization with plaque 
staining (n=10,10,10 animals with 21 plaques per animal on average). Scale bar 10 µm. 
*/**=p<0.05/0.01. Data are presented as mean ± SEM. 
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Figure 4: Influence of plaque structure and size on amyloid-associated neuritic dystrophy. 
a, Immunofluorescent costaining of APP (red) with qFTAA (blue) / hFTAA (green) and 
quantification of normalized amyloid-associated APP positive area (n=10,10,10 mice with 22 
plaques per animal on average). */**=p<0.05/0.01. Scale bar 10 µm. Data are presented as mean ± 
SEM. b, Whole model plot depicting actual against predicted APP areas based on 192 plaques of 11 
APP23 control mice at 12 months of age. c, Effect leverage plots and parameter estimates 
demonstrating the significant influence of plaque area and core qFTAA/hFTAA ratio on the amount 
of plaque-associated neuritic dystrophy. F(2,189)=184.5889, p<0.0001. 
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Supplementary Figure 1: Influence of the age of peripheral immune stimulation on plaque 
morphology and plaque-associated microglial numbers. 
a, Experimental design. b, Emission intensities at 502 / 588 nm for PBS (n=17), 1xLPS (n=10,5), 
and 4xLPS (n=11,6) treated animals stimulated at 3 or 7 months of age. c, Stereological 
quantification of plaque-associated microglia for PBS (n=14,), 1xLPS (n=9,5), and 4xLPS (n=10,6) 
treated animals stimulated at 3 or 7 months of age. */**/***=p<0.05/0.01/0.001. Data are presented 
as mean ± SEM. 
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Supplementary Figure 2: Alterations in plaque morphology in 9 months old APP23 animals 
after peripheral immune stimulation at 3 or 7 months 
a, Experimental design. b, Micrographs depicting representative plaque morphologies in the 
different treatment groups after hFTAA staining and ratio of emission intensities at 545 / 588 nm 
(n=9,9,9) revealed alterations in plaque structure after 4xLPS treatment. c, Experimental design. d, 
Micrographs depicting representative plaque morphologies in the different treatment groups after 
hFTAA staining and ratio of emission intensities at 545 / 588 nm (n=8,5,7) revealed no alterations 
in plaque structure between treatment groups. Scale bar 10 µm. */**=p<0.05/0.01. Data are 
presented as mean ± SEM. 
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Supplementary Figure 3: Absence of alterations in Aβ pathology and age of onset of plaque 
deposition after peripheral immune stimulation. 
a, Western Blot and quantification of normalized signal intensities demonstrating equal levels of 
APP and CTF-β between treatment groups (n=5,5,4). b, Quantification of mean plaque area and 
mean Congo red positive area in 12 months old APP23 animals (n=11,9,10). c, Experimental design 
for data in (d) and (e). d, Quantification of Aβ positive staining in 6 months old APP23 animals 
(n=5,4,5). e, ELISA measurement of total brain Aβ levels in 6 months old APP23 animals 
(n=5,4,5). Data are presented as mean ± SEM. 
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Supplementary Figure 4: Number of plaque-associated astrocytes and peripheral cytokine 
levels in 12 months old APP23 animals. 
a, ELISA measurement of serum cytokine levels (n=9,6,9) revealed no significant alterations 
between treatment groups. b, Micrograph and quantification of GFAP positive plaque-associated 
astrocytes (n=6,6,6) revealed no differences between treatment groups. Scale bar 10 µm. 
*/**=p<0.05/0.01. Data are presented as mean ± SEM. 
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4 Appendix 
4.1 Abbreviations 
Aβ    Amyloid beta 
AD    Alzheimer’s disease 
APP    Amyloid precursor protein 
ATP    Adenosine triphosphate 
BBB    Blood-brain barrier 
BCG    Bacillus Calmette-Guérin 
BrdU    Bromodeoxyuridine 
CTF    C-terminal fragment 
DAMP    Danger-associated molecular pattern 
GWAS   Genome-wide association studies 
hFTAA   Hepta-formyl thiophene acetic acid 
HIF    Hypxia-inducible factor 
LCO    Luminescent conjugated oligothiophene 
LDTF    Lineage-determining transcription factor 
LPS    Lipopolysaccharide 
mTOR    Mechanistic target of rapamycin 
NAD    Nicotinamide adenine dinucleotide 
NFT    Neurofibrillary tangle 
NSAID   Non-steroidal anti-inflammatory drug 
PAMP    Pathogen-associated molecular pattern 
PRR    Pattern-recognition receptor 
qFTAA   quadro-formyl thiophene acetic acid 
Rap    Ras-related protein 
ROS    Reactive oxygen species 
SDTF    Signal-dependent transcription factor 
WGCNA   Weighted gene correlation network analysis 
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